

PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	Bo	
Search	PubMed	<input type="checkbox"/>	for					Go	Clear
<input checked="" type="checkbox"/> Limits	Preview/Index		History		Clipboard		Details		
Display	Abstract	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Save	Text	Clip Add	Order	

Entrez PubMed

☐ 1: Radiology 1979 Jan;130(1):241-4Related Articles, [NEW Books](#), [LinkOut](#)

## Pharmacologic enhancement of gallium-67 tumor-to-blood ratios for EMT-6 sarcoma (BALB/c mice).

PubMed Services

Larson SM, Rasey JS, Grunbaum Z, Allen DR.

At various intervals after intravenous injection of carrier-free  $^{67}\text{Ga}$ -citrate, iron dextrane or deferoxamine mesylate was injected into EMT-6 tumor-bearing BALB/c mice. After treatment, rapid clearance of  $^{67}\text{Ga}$  from soft tissues was observed. Tumor uptake was not greatly affected, and so increased tumor-to-blood ratios were observed. The authors conclude that these drugs can enhance target-to-nontarget uptake ratios for tumors.


Related Resources

PMID: 758657 [PubMed - indexed for MEDLINE]

Display	Abstract	<input type="checkbox"/>	Sort	<input type="checkbox"/>	Save	Text	Clip Add	Order
---------	----------	--------------------------	------	--------------------------	------	------	----------	-------

[Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)  
[Department of Health & Human Services](#)  
[Freedom of Information Act](#) | [Disclaimer](#)

i686-pc-linux-gnu Apr 30 2002 10:28:00



 **1: U54705. Mus musculus tumo...**[\[gi:1490512\]](#) [ProbeSet](#), [Related Sequences](#), [Protein](#), [Taxonomy](#), [UniSTS](#), [LinkOut](#)


1	ctccttcggc	tttttcccc	cttttgcatc	ttgtttcccg	ggatacctgc	aactcaaggt
61	ctaaggtaca	aattgcaatc	ctgtccatgc	acttgtctct	aacacaccag	tgggtcctat
121	ctaaggaagc	ctttgacctt	gagtcgtgaa	actgtctctc	tgacctggg	gtgcacatcc
181	tgtccgagga	tggatgcctt	gagactggca	aattcagctt	ttgtctgttg	cttgttcaaa
241	caactatgtg	aaagggacc	agcaggaaac	attctcttct	ctccaatatg	cctctctact
301	tctctgtccc	tgtgcgaagt	gggcacaaa	ggcgacatgc	caaatgaat	tggcacaggtc
361	cttcattttt	agaattgtcaa	agatgtacc	tttgggttc	aaacagtcac	ttctgatggt

```
421 aataagctca gttcttttta ctctttgaaa cttgtcaagc gactctacat agacaaatct
481 ctgaaccctt ctacagaatt tatcagttct accaaaagac catatgcaaa agaattggaa
541 actggttgact tcaaagacaa actggaagaa acgaaaggct aaattaacag ctccattaag
601 gagctcacag atggccactt tgaggacatt ttgtcagaga acagtataag tgaccagacc
661 aaaatccttg tggttaatgc tgcctacttt gttggaaagt ggatgaagaa atttccggaa
721 tcagaaacaa aagaatgtcc ttccagaatc agcaagacag acaccaaacc cgtacaaatg
781 atgaatcttg aggccacttt ctgcttgggt aacattgatg acatcagctg taagatcata
841 gaacttcctt tccagaataa gcatctgagt atgctcattg tgctcccaa ggacgtggag
901 gatgagtcca caggcctgga gaagattgaa cagcaactca acccagaaac attgttacag
961 tggaccaacc ccagtaccat ggccaatgcc aaagtcaaac tttccctccc aaagtttaag
1021 gtagaaaaga tgattgatcc caaggctagt ctggaaagcc tagggctgaa aagtctcttc
1081 aatgaaagta catcggattt ctctggaatg tcagagacca agggagtgtc cctgtcaaat
1141 gtgattcata gagtatgcct agaaataacc gaagatggtg gtgagtccat cgaggtgcca
1201 ggggtcccga tcttacagca caaggatgaa ttcaatgctg accatccatt tatttatatc
1261 attagacaca acaaaactcg aaacatcatt ttctttggca aattctgttc tccttagctg
1321 gcagggcctt gccaagtctc agggaaactg tctgtagtcg cagagctctg taaactttgt
1381 atccagacaa tcactttcta tacaataaat tgtaaattgt gctgaatcag ga
```

//

Revised: October 24, 2001.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



*mel-14 human homolog*  
☐ 1: M25280. Human lymph node  
 ...[gi:187182] Related Sequences, OMIM, Protein, PubMed, Taxonomy, UniSTS, LinkOut

no hits

```

FEATURES             Location/Qualifiers
     source            1..2354
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
     gene            1..2354
                        /gene="LNHR"
     CDS             116..1234
                        /gene="LNHR"
                        /note="lymph node homing receptor precursor"
                        /codon_start=1
                        /protein_id="AAC63053.1"
                        /db_xref="GI:307134"
                        /db_xref="GDB:G00-118-834"
                        /translation="MIFPWKCQSTQRDLWNI FKLWGWTMLCCDFLAHHGTDCWTYHYS
EKPMNWQRRARFRDNYTDLVAIQNKAIEIYLEKTL PFSRSYYWIGIRKIGGIWTWVG
TNKSLTEEAENWGDGE PNNKKNKEDCVEIYIKRNKDAGKWND DACHKLKAALCYTASC
QPWSCSGHGCVEI INNYTCNCDVGYYPQCQLVIQCE PLEAPELGTMDCTHPLGNFS
FSSQCAFSCSEGTNLTGIEETTCGPFGNWSSPEPTCQV IQCEPLSAPDLGIMNC SHPL
ASFSTACTFICSEGT ELIGKKKTICSSGISNPSPIQCKL DKSFSMIKEGDYNPL
FIPVAVMVTA FSGLA FIIWLARRLKKGKKSGRSMNDPY"

```


1	gagtgcagtc	tacctgcagc	acagcacact	cctttgggca	aggacctgag	acccttgtgc
61	taagtcaaga	ggctcaatgg	gctgcagaag	aactagagaa	ggaccaagca	aagccatgat
121	atttccatgg	aaatgtcaga	gcaccagag	ggacttatgg	aacatcttca	agttgtgggg
181	gtggacaatg	ctctgttggtg	atttcctggc	acatcatgga	accgactgct	ggacttacca
241	ttattctgaa	aaacccatga	actggcaaag	ggctagaaga	ttctgccgag	acaattatcac
301	agatttagtt	gccatacaaa	acaaggcgga	aattgagtat	cttgagaaga	ctctgccttt
361	cadtccttct	tactatacga	taggaatccq	qaagatagga	ggaatatgga	cgtgggtggg

```
421 aaccaacaaa tctcttactg aagaagcaga gaactgggga gatggtgagc ccaacaacaa
481 gaagaacaag gaggactgcg tggagatcta tatcaagaga aacaaagatg caggcaaatg
541 gaacgatgac gcctgccaca aactaaaggc agccctctgt tacacagctt cttgccagcc
601 ctggtcatgc agtggccatg gagaatgtgt agaaatcatc aataattaca cctgcaactg
661 tgatgtgggg tactatgggc cccagtgtca gcttgtgatt cagtgtgagc ctttggaggc
721 cccagagctg ggtaccatgg actgtactca ccctttggga aacttcagct tcagctcaca
781 gtgtgccttc agctgctctg aaggaacaaa cttaactggg attgaagaaa ccacctgtgg
841 accatttggg aactggtcac ctccagaacc aacctgtcaa gtgattcagt gtgagcctct
901 atcagcacca gatttgggga tcatgaactg tagccatccc ctggccagct tcagctttac
961 ctctgcatgt accttcacat gctcagaagg aactgagtta attgggaaga agaaaaccat
1021 ttgtgaatca tctggaatct ggtcaaatcc tagtccaata tgtcaaaaat tggacaaaag
1081 tttctcaatg attaaggagg gtgattataa cccctctctc attccagtgg cagtcatggt
1141 tactgcattc tctgggttgg catttatcat ttggctggca aggagattaa aaaaaggcaa
1201 gaaatccaag agaagtatga atgaccata ttaaactgcc cttggtgaaa gaaaattctt
1261 ggaatactaa aaatcatgag atccttttaa tccttccatg aaacgttttg tgtggtggca
1321 cctcctacgt caaacatgaa gtgtgtttcc ttcagtgcac ctgggaagat ttctaccgca
1381 ccaacagttc cttcagcttc catttcgccc ctcatttatc cctcaacccc cagcccacag
1441 gtgtttatac agctcagctt tttgtctttt ctgaggagaa acaataaga ccataaaggg
1501 aaaggattca tgtggaatat aaagatggct gactttgctc tttcttgact cttgttttca
1561 gtttcaattc agtgctgtac ttgatgacag acacttctaa atgaagtgca aatttgatac
1621 atatgtgaat atggactcag ttttcttgca gatcaaattt cacgtcgtct tctgtatact
1681 gtggaggtac actcctatag aaagttcaaa aagtctacgc tctcctttct ttctaactcc
1741 agtgaagtaa tggggctcctg ctcaagttga aagagtccta tttgcactgt agcctcgccg
1801 tctgtgaatt ggaccatcct atttaactgg ctccagcctc cccaccttct tcagccacct
1861 ctctttttca gttggctgac ttccacacct agcatctcat gagtgccaa gcaaaaggaga
1921 gaagagagaa atagcctgcg ctgtttttta gtttgggggt tttgctgttt ccttttatga
1981 gaccatttcc tatttcttat agtcaatgtt tcttttatca cgatattatt agtaagaaaa
2041 catcactgaa atgctagctg caagtgcacat ctctttgatg tcatatggaa gagttaaaac
2101 aggtggagaa attccttgat tcacaatgaa atgctctcct ttcccctgcc cccagaactt
2161 ttatccactt acctagattc tacatattct ttaaatttca tctcaggcct ccctcaaccc
2221 caccatttct tttataacta gtcctttact aatccaaccc atgatgagct cctcttctctg
2281 gcttcttact gaaaggttac cctgtaacat gcaattttgc atttgaataa agcctgcttt
2341 ttaagtggga attc
```

//

Revised: October 24, 2001.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



 **1: U04313. Human maspin mRNA...**[\[gi:453368\]](#) [Related Sequences, OMIM, Protein, PubMed, Taxonomy, UniSTS, LinkOut](#)


1 of 2

polyA signal 2545..2550  
BASE COUNT 786 a 526 c 504 g 750 t  
ORIGIN  
1 ggcacgagtt gtgctcctcg cttgcctggt ccttttccac gcattttcca ggataactgt  
61 gactccaggc ccgcaatgga tgccctgcaa ctacgaaatt cggcttttgc cgttgatctg  
121 ttcaaacaac tatgtgaaaa ggagccactg ggcaatgtcc tcttctctcc aatctgtctc  
181 tccacctctc tgtcacttgc tcaagtgggt gctaaaagggtg acactgcaaa tgaaattgga  
241 caggttcttc attttgaaaa tgtcaaagat ataccctttg gatttcaaac agtaacatcg  
301 gatgtaaaca aacttagttc cttttactca ctgaaactaa tcaagcggct ctacgtagac  
361 aaatctctga atctttctac agagttcatc agctctacga agagacccta tgcaaaggaa  
421 ttggaaactg ttgacttcaa agataaattg gaagaaacga aaggtcagat caacaactca  
481 attaaggatc tcacagatgg ccacttttag aacatttttag ctgacaacag tgtgaacgac  
541 cagacaaaaa tccttgtggt taatgctgcc tactttgttg gcaagtggat gaagaaattt  
601 cctgaatcag aaacaaaaga atgtcctttc agactcaaca agacagacac caaaccagtg  
661 cagatgatga acatggaggc cagtttctgt atgggaaaca ttgacagtat caattgtaag  
721 atcatagagc ttccttttca aaataagcat ctcagcatgt tcatcctact acccaaggat  
781 gtggaggatg agtccacagg cttggagaag attgaaaaac aactcaactc agagtactg  
841 tcacagtgga ctaatcccag caccatggcc aatgccaagg tcaaaactct cattccaaaa  
901 tttaagggtg aaaagatgat tgatcccaag gcttgtctgg aaaatctagg gctgaaacat  
961 atcttcagtg aagacacatc tgatttctct ggaatgtcag agaccaaggg agtggcccta  
1021 tcaaatgtta tccacaaagt gtgcttagaa ataactgaag atggtgggga ttccatagag  
1081 gtgccaggag cacggaatcct gcagcacaag gatgaattga atgctgacca tccctttatt  
1141 tacatcatca ggcacaacaa aactcgaaac atcattttct ttggcaaatt ctgttctcct  
1201 taagtggcat agcccatggt aagtccctccc tgacttttct gtggatgccg atttctgtaa  
1261 actctgcatc cagagattca ttttctagat acaataaatt gctaattgtg ctggatcagg  
1321 aagccgccag tacttgtcat atgtagcctt cacacagata gacctttttt tttttccaat  
1381 tctatctttt gtttctttt ttcccataag acaatgacat acgcttttaa tgaaaaggaa  
1441 tcacgttaga ggaaaaatat ttattcatta tttgtcaaat tgtccggggt agttggcaga  
1501 aatacagtct tccacaaaga aaattcctat aaggaagatt tggaagctct tcttcccagc  
1561 actatgcttt ccttcttttg gatagagaat gttccagaca ttctcgcttc cctgaaagac  
1621 tgaagaaagt gtagtgcatt ggaccacga aactgccctg gctccagtga aacttgggca  
1681 catgctcagg ctactatagg tccagaagtc cttatgttaa gccctggcag gcaggtgttt  
1741 attaaaattc tgaatttttg ggattttcaa aagataatat ttacataca ctgtatgtta  
1801 tagaacttca tggatcagat ctggggcagc aacctataaa tcaaacacct aatatgctgc  
1861 aacaaaatgt agaattattc gacaaaatgg atacataaag actaagtagc ccataagggg  
1921 tcaaaatttg ctgccaaatg cgtatgccac caacttaca aaacacttcg ttcgcagagc  
1981 ttttcagatt gtggaatggt ggataaggaa ttatagacct ctagtactg aaatgcaaga  
2041 cccaagagg aagttcagat cttaataata attcactttc atttttgata gctgtcccat  
2101 ctggtcatgt ggttggcact agactggttg caggggcttc tagctgactc gcacagggat  
2161 tctcacataa gccgatatca gaatttgtgt tgaaggaaat tgtctcttca tctaataatga  
2221 tagcgggaaa aggagaggaa actactgcct ttagaaaata taagtaaagt gattaaagt  
2281 ctcacgttac cttgacacat agtttttcag tctatgggtt tagttacttt agatggcaag  
2341 catgtaactt atattaatag taatttgtaa agttgggttg ataagctatc cctgttgccg  
2401 gttcatggat tacttctcta taaaaaatat atatttacca aaaaattttg tgacattcct  
2461 tctcccatct cttccttgac atgcattgta aataggttct tcttgttctg agattcaata  
2521 ttgaatttct cctatgctat tgacaataaa atattattga actacc

//

Revised: October 24, 2001.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	Book
Search		Nucleotide	for			Go	Clear	
Limits		Preview/Index		History		Clipboard		Details
Display	default	Save	Text	Add to Clipboard				

☐ 1: L24118. Mouse primary  
res...[gi:400371]

ProbeSet, Related Sequences, Protein, PubMed, Taxonomy,  
UniSTS, LinkOut

LOCUS MUSB94A 3512 bp mRNA linear ROD 14-JUL-1994  
DEFINITION Mouse primary response gene B94 mRNA, 3'end.  
ACCESSION L24118  
VERSION L24118.1 GI:400371  
KEYWORDS  
SOURCE Mus musculus cDNA to mRNA.  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE 1 (bases 1 to 3512)  
AUTHORS Wolf, F.W., Sarma, V., Seldin, M., Drake, S., Suchard, S.J., Shao, H.,  
O'Shea, K.S. and Dixit, V.M.  
TITLE B94, a primary response gene inducible by tumor necrosis  
factor-alpha, is expressed in developing hematopoietic tissues and  
the sperm acrosome  
JOURNAL J. Biol. Chem. 269 (5), 3633-3640 (1994)  
MEDLINE 94148868  
PUBMED 8106408  
FEATURES Location/Qualifiers  
source 1..3512  
/organism="Mus musculus"  
/db\_xref="taxon:10090"  
CDS 106..2058  
/codon\_start=1  
/protein\_id="AAA72044.1"  
/db\_xref="GI:402160"  
/translation="MSEASSEDLMPSPEAPDGEEESAKKKEKKSGLANMFSVFTKGK  
KKKKDQPRLSDELVQPKPRPELDGPLPTVEELKEALEHGRLEVAWQVLALERQLEAAA  
AAGGMSNEELVWRQSKVEALYVLLCDQVLGVLRRPLEAAPERLSQALAVVSQEELEDR  
RASGGPLAAALEATRPRRWLQWRGVVAEVAERLDAQPATAPEGRSEAESRFLHMGR  
TMKEDLEVVERLKLPLFPDEFNVVRTYAESYHYHFASHLCALAQFELCERDTYLLLLW  
VQNLYPNDILNSPKLAQELQGVGLGSLPPKQIRLLEAMFLSNEVTSVKQLMARALEL  
ESQRWTQDVAPQSLDGHCHSELAIDILQIISQGQTKAENITSDVGMQIKQLLLVELAA  
LLRSYQRAFDEFLEKSKLLRNRYRVNIMANINNCLFFWTSVEQKWQISHDSLNRLLLEPL  
KDLKAHGFDTLLQSLFDLKLPLFKKFTQTRWANPVETLEEIIITVSSSLPEFSELQDC  
FREELMETVHLHLVKEYIIRLCKRRLVLKTAEQQQLARHILANADAIQGFCTENGST  
ATWLHRALPMIAEIIRLQDSSAIKIEVATYATWYPDFSKGHLNAILAIKGNLPSSEVR  
SIRNILDINTGVQEP RPPLFLSLIKVT"  
BASE COUNT 792 a 965 c 993 g 762 t  
ORIGIN  
1 ttcttccaag ggtttcctgg ccagcagtct gtgccaggga ccctgaactt cgctgtaagc  
61 ccccaaaagc cagcgtctac atccgaggct gaatcagaga cctccatgtc tgaggcgctc  
121 tctgaggacc tgatgccatc cccggaggct cccgatgggg aggaggagtc tgcaagaag  
181 aaggagaaga agtccaaagg actggccaac atgttcagtg tcttcaccaa agggaaaaag  
241 aaaaaaaagg accagcccag attatcagat ctggaagtgc agcccaagcc caggcccag  
301 ttagatggtc cactgcccac agtggaggag ctcaaggagg ccctggagca cgggcggctg  
361 gaggtggcct ggcaggtgct ggcgttggag aggcagctcg aggctgcggc agcggcggt  
421 ggcagtgaca acgaggagct ggtgtggcgg cagagcaagg tggaggctct gtacgtgctg  
481 ctttgcgacc aggtgctcgg ggtactgcgg cggccgctgg aggcggcgcc cgagcggctg




```
541 agccaggcgc tagccgtggt gtcgcaggag gagctcgagg accggcgggc gtccggggga
601 cccttggcgg cggcactgga ggccacgcgc ccgcggcgat ggctgcagcg gtggaggggc
661 gtcgtggcgg aggtggcagc ggaacgtctg gacgcgcagc cggccacagc gcccaggggc
721 cgctcggagg cggagagcag gttcctgcac atgggtcgca ccatgaagga ggacctggag
781 gtggtggtgg agaggctgaa gccgctgttc cccgacgagt tcaacgtcgt gcgcacctac
841 gccgaaagct accactacca cttcgccagc caccgtgtcg ccttggcgca gttcgagttg
901 tgtgaaaggg atacctactt gctgctgctc tgggtgcaga acctctaccc caatgatatt
961 ctcaacagcc cgaagtggc acaggagctt caaggtgtcg ggcttgggag cctcctgccc
1021 ccaaagcaga tcagattgct ggaggccatg ttcttgtcca atgaggtgac cagcgtgaag
1081 cagctcatgg cccgagcttt agagctggag tctcagcgct ggaccagga tgtggctccc
1141 cagagcctgg atggccactg tcacagttag ctggccatcg acattctcca gatcatttca
1201 caaggccaga ctaaggctga gaacatcact tcggacgtgg ggatgcagat aaagcagttg
1261 ctgctggtgg agctggctgc actactgagg agctaccagc gcgcctttga tgagtttcta
1321 gagaagagca aactcctgag gaattacaga gtcaacatca tggccaacat caacaactgc
1381 ctgttcttct ggacttccgt ggagcagaaa tggcagatat ctcagtattc tctgaaccgc
1441 ctgctggagc ctttgaaaga cctcaaggcc ctggtctcg acacctgct ccagagccta
1501 tttttggacc tgaagccgct gtttaagaag ttcacacaga cccgttgggc aaatccagtt
1561 gagaccctgg aggaaatcat cactactgtg agcagcagcc tgcctgaatt ctgagagctg
1621 caggactggt tccgggagga gctcatggag actgtgcacc tgcacctagt gaaagaatac
1681 atcatcaggc tctgcaaacg gcgcctggtc ctcaagacgg ccgagcagca gcagcagctg
1741 gcaaggcaca tcctggccaa cgcggatgcc attcaggggt tctgcaactg gaatggctcc
1801 actgcaacct ggctgcaccg cgccctccct atgattgctg agatcattcg cctgcaagat
1861 tccagtgcga ttaagatcga ggtggccaca tacgccactt ggtaccctga aactagcaaa
1921 ggccacctga acgccatcct ggccatcaag ggcaatctac caagcagtg agtcagagc
1981 atccggaaca tactggacat caacacggga gtgcaggagc ctcccaggcc cctgttctcc
2041 cttataaagg ttacttagct tttctgaagg tctgatatgc taatgaggcc cagggaacac
2101 caggcaccac accagttggg gatgctcagt ggctccagct ccatgacca tcatcaggct
2161 cccacattct gctgttgctt ctgcccagcc ctggctctgg aacaagatct gacagccaag
2221 atcgcacaga tgatggatcc agtgggggtc agacctcact gaagggagct gacatctgag
2281 catgcaagag atttcttgta aatgattatt catcttgggt agagtgaact ttgtctacct
2341 aactgtagt ctgcctttta acggtctgag ttgccctgtc cagctcccta ggtcagggg
2401 tgaagcctca tttataccat ttctctcagc ccagggatgt catgagatag aactaaaaac
2461 aagggaagaa agaagaacta gtatctgacc cggggcctgg aagcaggcct gtgaagtgcc
2521 catgacagag ctagacctg caaagtgtcc cctggtacca ctgagctagc aggacctct
2581 tattcactcc ccatgggctg ccctgcccct ctgtgtgtgt atggatgtgt ttgggaagtg
2641 accctggaag ccttcgcaga gcagggacct ccgggttct ctgagatcaa atcttcttgc
2701 atttaggaat aagccagagg ccacogtctg gagtctggtg ggagtgcagg ggtctggcaa
2761 gtgctttact ggcttccgtg tgggtgctgt ccaaacttcc acggcaagtg ggcttgaact
2821 accacttttc cttcagttct gcaaatacaca agtctattat cagactgaag tctaaatgtg
2881 gtcagggccc actgectctg gaagccccag ggagaattgt ttctgggtct tcccagctct
2941 ttagaggtta ccccatctt ttgtctgagg accttgtaac ttcagagcca gggacagcta
3001 catatgctcc tcacaccacc acagtctcca ctggttcgga tcccactgtg acttaggatac
3061 cccgtgactg cagtgaatct gccagagac tcagcagcca cccattaac taactcctgt
3121 caccataatg tcattggctc tggggaccag tgggtcccac gggggctaca ctggaaaaca
3181 gcaaggcagt ttgccatcaa ggcacctgct actccacaga tctgctcct ctctagccat
3241 gagagctctt ctcggcactg gccagcctt gacttgtcat gattcgagge tgggatttga
3301 agcttctcct ctgtcccctc cccaggtac ttgctggagc tggccagggt gagcagcaca
3361 cacagccttt gtattcttgt agacgaccgc tgttgatgac attaataatt ttaataattat
3421 ttttatagtg ttggttttgt atgtgtgtac tcaggacaga atccagagat ttctttttta
3481 tatagcttga tataaaacag atttcaaaag tg
```

//

Revised: October 24, 2001.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



**1: M25324. Mouse peripheral** ProbeSet, Related Sequences, OMIM, Protein, PubMed,  
**...[gi:198803]** Taxonomy, UniSTS, LinkOut


5/3/02 7:04 PM


```
1  gaattctcga gctcgtcgac cagccctcc ttgtgcaaga actctgagcc ccaggtgcag
61  gaggtcagga cctgcagaga gacttgcaga gagaccagc aagccatggt gtttccatgg
121 agatgtgagg gtacttactg gggctcgagg aacatcctga agctgtgggt ctggacactg
181 ctctgttgtg acttcctgat acaccatgga actcactgtt ggacttacca ttattctgaa
241 aagcccatga actgggaaaa tgctagaaag ttctgcaagc aaaattacac agatttagtc
301 gccatacaaa acaagagaga aattgagtat ttagagaata cattgcccaa aagcccttat
361 tactactgga taggaatcag gaaaattggg aaaatgtgga catgggtggg aaccaaaaa
421 actctcacta aagaagcaga gaactggggt gctggggagc ccaacaacaa gaagtccaag
481 gaggactgtg tggagatcta tatcaagagg gaacgagact ctgggaaatg gaacgatgac
541 gcctgtcaca aacgaaaggc agctctctgc tacacagcct cttgccagcc agggctctgc
601 aatggccgtg gagaatgtgt ggaaactatc aacaatcaca cgtgcatctg tgatgcaggg
661 tattacgggc cccagtgtca gtatgtgggt cagtgtgagc ctttggaggc ccctgagttg
721 ggtaccatgg actgcatcca ccccttggga aacttcagct tccagtccaa gtgtgctttc
781 aactgttctg agggaagaga gctacttggg actgcagaaa cacagtgtgg agcatctgga
841 aactggtcac ctccagagcc aatctgccaa gtggtccagt gtgagccttt ggaggccctt
901 gagttgggta ccatggactg catccacccc ttgggaaact tcagcttcca gtccaagtgt
961 gctttcaact gttctgaggg aagagagcta cttgggactg cagaaacaca gtgtggagca
1021 tctggaaact ggtcatctcc agagccaatc tgccaagaga caaacagaag tttctcaaag
1081 atcaaagaag gtgactacaa cccctcttcc attcctgtag ccgtcatggt caccgcattc
1141 tcggggctgg catttctcat ttggctggca aggcggttaa aaaaaggcaa gaaatctcaa
1201 gaaaggatgg atgatccata ctgattcatc ctttgtgaaa ggaaagccat gaagtgttaa
1261 agacaaaaca ttggaaaata acgtcaagtc ctcccgtgaa gattttacac gcaggcatct
1321 cccacattag agatgcagtg tttgctcaac gaatctggaa ggatttcttc atgaccaaca
1381 gctcctccta atttcccctc gctcattcat cccattaacc ctatcccata atgtgtgtct
1441 atacagagta gtattttatc atcttttctg tggaggaaca agcaaaagtg ttactgtaga
1501 atataaagac agctgctttt actctttcct aactcttgtt tcttagttca attcagcaca
1561 gaagctaata ccaaacacag tgaatatatg atccatgagt aattggaaac tcagactcct
1621 tgcgcatagt acgtacccta tgtaacatcg acaaaaatct ttcatttcca cctccaaaga
1681 acagtgtctt attcaagttg ggaaagtctt acttctctct tagaccact atctgtgagt
1741 gacagccact gtagctgttc acattaacct tccccatctc cttttcctag gagaataatt
1801 ccacacactg caccctatga tggccaccaa acatcaaaga agggaaaatc tctgcattg
1861 agtttttagt ttgagttttc cttctctttt attagatctc tgatgggtcc ttgaagtcag
1921 tgttctgatg attattaata gttaatgata acacaacca ctctcttgga gctgatgta
1981 tgaagacaac aggtagaaaa attcctgggc tcaggctgga gtgacacct tttctttccc
2041 taacatcttc tactcagata cctaaattta agattcagga cagctgtccc caactcttac
2101 catgtctttt ataacttgct ccttaacttg cccaacctgt aggtatctc atttctctgc
2161 ttcactctgc aaggtttata acatgatgaa tttaaatac
```

//

Revised: October 24, 2001.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)



 **1: X85993. M.musculus mRNA**  
f...[gi:854329]

```

FEATURES             Location/Qualifiers
     source            1..2913
                        /organism="Mus musculus"
                        /strain="NMRI"
                        /db_xref="taxon:10090"
                        /clone="semaf18"
                        /clone="semae9"
                        /clone_lib="Stratagene lambda ZAP"
                        /dev_stage="12 days embryo"
     gene            111..2429
                        /gene="semD"
     CDS             111..2429
                        /gene="semD"
                        /codon_start=1
                        /product="semaphorin D"
                        /protein_id="CAA59985.1"
                        /db_xref="GI:854330"
                        /db_xref="MGD:107558"
                        /db_xref="SPTREMBL:Q62180"
                        /translation="MGWFTGIACLFWGVLLTARANYANGKNNVPRKLKSYKEMLESNN
VITFNGLANSSSYHTFLLDEERSRLYVGAKDHIFSNLVNIKDFQKIVWPVSYTRRDE
CKWAGKDILKECANFIKVL EAYNQTHLYACGTGAFHPIC TYIEVGHHPEDNIFKLQDS
HFENGRGKSPYDPKLLTASLLIDGELYSGTAADEFMRDFAIFRTLGDHHPIRTEQHDS
RWLNDPRFISAHLIPESDNPEDDKVYFFFRENAIGGEHSGKATHARIGQICKNDFGGH
RSLVNKWTTF LKARLICSVPGPNGIDTHFDELQDVF L MNSKDPKNPIVYGVFTTSSNI
FKGSAVCMYMSDVR RVFLGPY AHRDGP NYQWVPYQGRVPYPRPGT CPSKTFGGFDST
KDL PDDVIT EGRSH PAMYNPVFPINNRPIMIKTDVNYOFTOI VVDRVDAEDGOYDVM

```

IGTDVGTVLKVVSPKETWHDLLEEVLLLEMTVFREPTTISAMELSTKQQQLYIGSTAG  
 VAQLPLHRCDIYGKACAECCLARDPYCAWDGSSCSRYFPTAKRRTRRRQDIRNGDPLTH  
 CSDLEDHDNHHGPSLEERIIYGVENSSTFLECSPKSQRALVYWQFQRRNRRSKREIRM  
 GDHIIRTEQGLLLRSLQKKDSGNLYLCHAVEHGFMTLLKVTLEV IDTEHLEELLHKDD  
 DGDGSKIEMSSSMTPSQKVWYRDFMQLINHPNLNTMDEFCEQVWKRDRKQRRQRPQH  
 SQGSSNKWKHMQESKKGRNRRTHEFERAPRSV"

BASE COUNT            888 a       632 c       679 g       714 t  
 ORIGIN



```

1  actgatctaa atcacctgtt acctccagtt tccagattgt ttgaacttct ctggacgcac
61 aatacaggaa ggaaggctgt cgcagctcag ggacctccag cgtctgcagc atgggctggt
121 tcaactggat tgcctgtctt ttctgggggtg tattacttac agccagagca aactatgcaa
181 acggaagaaa caatgtgcca agactgaaat tatcgtacaa agaaatgttg gaatccaaca
241 atgtgatcac ttttaatggc ttggccaaca gctccagtta ccacaccttc cttctggatg
301 aagaacggag tagactatat gttggagcaa aagatcatat attttcattc aacttgggtga
361 acattaaaga ttttcaaaag attgtgtggc cagtatctta cacaaggaga gatgaatgca
421 aatgggctgg aaaagatatc ctgaaagaat gtgccaattt catcaaggtc ctggaggctt
481 ataatacagac tcacttgtat gcctgtggaa ctggggcttt ccatccaatc tgcacctata
541 ttgaagttgg acatcatcct gaggacaaca tttttaagct gcaggactca cattttgaaa
601 acggctcgtg gaagagccct tatgatccca aactactgac tgcctctctt ctaatagacg
661 gtgagttgta ctctggaact gctgcggaact tcatgggacg ggacttcgct atcttcagaa
721 cactggggga ccatcacccc atcaggacgg agcagcatga ctcccgggtg ctcaatgatc
781 ctagattcat cagtgcccat ctcatccag agagtgacaa ccctgaagat gacaaagtat
841 attttttctt ccgagaaaaa gcaataggcg gagaacactc tggaaaagcc atcatgcta
901 gaataagtcg gatatgcaag aatgactttg gtggacacag aagtcttgtg aataaatgga
961 caacattcct aaaagcacgc ctgatttgc tctgtcccgg tcccaatggc attgacaccc
1021 attttgatga attgcaggat gtattcctaa tgaactctaa agatcctaaa aatccgatcg
1081 tctatggagt gttcacaaca tcaagcaaca tctttaaggg atctgctgtg tgcattgaca
1141 gcatgagtga tgaagaagg gtgttccttg gtccatatgc tcacagagat ggtcccaact
1201 atcagtgggt gccttaccaa ggaagagttc cttatccacg gccaggaact tgtcccagta
1261 aaacatttgg cggatttgac tccacaaaag accttccctga tgatgtcata acttttggaa
1321 gaagtcatcc agccatgtac aacccagtg ttcctataaa taatcgcccc atcatgatca
1381 aaacagatgt aaattatcag ttcacacaaa ttgtttaga cagagtggat gcagaagatg
1441 gccagtatga tgttatgttc atcggaacag atgttggaa cgttcttaaa gtggtttcag
1501 tccccaagga gacttggcat gacctagaag aagttcttct ggaagaaatg accgtcttcc
1561 gggaaccaac aactatttct gcaatggagc ttttactaa acagcaacag ctgtacattg
1621 gctcaactgc gggagtggca cagcttcctc tacaccgctg tgacatctat ggcaaagcct
1681 gtgcagaatg ctgcctcgct cgggaccctt actgtgcctg ggatgggtcc tcatgctcac
1741 gctattttcc tactgcaaag aggcgcacaa gacgacaaga tataaggaat ggagaccac
1801 tgactcactg ctctgacttg gaggaccatg ataatacatc tgggcccagc cttgaagaga
1861 gaatcatcta tggagtggaa aacagtagta cattcttgga atgcagtcg aagtcacaga
1921 gagccttgg tttatggcaa tttcagagga gaaatcgaag atcgaaaaga gagatcagaa
1981 tgggtgatca tatcatcagg acagaacaag ggctcctgct ccgtagcctg cagaagaagg
2041 attcaggcaa ttacctgtgt cacgctgtgg aacacggatt catgcaaact cttcttaagg
2101 taaccctgga agtcattgac acagaacatt tggagaact tcttcataaa gatgacgatg
2161 gagatggctc taagataaaa gaaatgtcga gcagcatgac gccagccag aaagtctggt
2221 accgagactt catgcagctc attaaccacc ccaacctgaa cacgatggat gagttctgtg
2281 aacaagtgtg gaaaagggac cgaaagcaac gccgacaaag gccggggcac tctcaaggga
2341 gcagcaacaa gtggaagcac atgcaagaga gcaagaaagg tagaaacagg aggaccacg
2401 agtttgagcg ggcaccacga agtgtctgag ctgcgccacc tcccaaaccc tcaacaagt
2461 acaaacttgc ttagataata actggaaaaa atgcaatata catgaacatt tcatggcatt
2521 atgtggatgt ttacaatgat gggaagttca accgggttcc accaatttaa gtccgtgagg
2581 aactttccca gcaggctttc ttcagtatac caacgcttga cagagatcac aggtgagcat
2641 agatgttcac gtccgctgac ttagtgtttc ctctgaaagt tcatattggt tcttctttg
2701 cctgagaaat aaaaatgtca tttgccatcg aaaggagaaa aactgcatca gcaaagccat
2761 tttattgaag caagagttga aaataaactg catggattta gtaagcagat gaatattcca
2821 aaacgtgatt ggattcaagg atgttttggc taccagcact cgtgtttgta tgtactggag
2881 aagtaaaata aggagaatga cactgagtga cat

```

//

Revised: October 24, 2001.



# Nucleotide

PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM Books

Search  for

Limits Preview/Index History Clipboard Details

☐ 1: W13166.ma93f11.r1 Soares...[gi:1287295]

ProbeSet, Taxonomy, Traces, LinkOut

**IDENTIFIERS**

**dbEST Id:** 520223  
**EST name:** ma93f11.r1  
**GenBank Acc:** W13166  
**GenBank gi:** 1287295

**CLONE INFO**

**Clone Id:** IMAGE:318285 (5')  
**Source:** IMAGE Consortium, LLNL  
**DNA type:** cDNA

**PRIMERS**

**Sequencing:** ETPrimer  
**PolyA Tail:** Unknown

**SEQUENCE**

```
GCCCTGAGTGTTCATGTGTCTGGGCCTTGCCTGCTTGGGGTCCTGCAGAGCCAGGCCAGG
ACTCAACTCAGAACTTGATCCCTGCCCCATCTCTGCTCACTGTCCCCCTGCAGCCAGACT
TCCGGAGCGATCAGTTCCGGGGCAGGTGGTACGTTGTGGGCCTGGCAGGCAATGCGGTCC
AGAAAAAACAGAAGGCAGCTTTACGATGTACAGCACCATCTATGAGCTACAAGAGAACA
ATAGCTACAATGTACCTCCATCCTGGTCAAGGACAGGACCAGGGCTGTCTGCTACTGGAT
CAGAACATTTGTTCCAAGCTCCAGGGCTGGCCAGTTCACTCTGGGAAATATGCACAGGTA
TCCTCAGGTACAGAGCTACAATGTGCAAGTGGCCACACGGACTACAACCAGTTGCGCATG
GTATTTTTCCGAAAGACTTGTGAAAACAAGCAATACTTCAAATTACGCTGTATGGAAGA
ACCAAGGAGCTGTGCGCTGAAGTGAAGGAACGTTTACCAGCTTTGCCAAGTCTCTGGGCC
TCAAGGANGAGAACATCATGTTCTCGTGTACGACGGACGAATGAATTGACACTTGAATT
GCGTGGTGAATGTGGCTGACTGGGAATCCAGAGCACCAATGGTTAGGCGCTGCTGGTC
TTGTGTGCGATCGCATGCTTCTGGTGCCGAGAGACCACCTTGATGCGCCAGCAGCGGCA
TTCCGAGGTGCGGTTTTGAGCGCGTGTGAATTGTGCACAGCTCGCGCTACTTGCTGTAGA
CAGAAGTGGAGCCGTTGTGGTTGATAGTGTGGCCCCGAGGAACATGTGAATTTGTGCGGGG
TGTCTCGTAGAGTGGGTATTTGTTTCGGAGCGTGTGAGACACGTGCGTGGGCACACGGTC
CTTCTCGTGGACCCTTTTCAGTGTGGTAGAAGCCGTGGTATCGGCTCCGCAGTCTGGTGCC
GCGTTCGTTTCGGGCTTTCTAAGGAATTCGGCGGTGTGTCGTCTAAGCCTATAACGCGTGGA
TCTCTCCAAAGGTGGTTCGAGTCTTGGGTTTTGTGAACGAGTTTTGGGTGACAAAAATGCG
CCGTGACACTCCTGGCGNNAGAGNNGNNGGGGTGGGGCGNGTGTGTGGTGGTGGGGGTGT
GGTGTGTGGTATGTGGGGGTGCGGGGGTAGTGGGGCTGGCTGCGGTGTCTGCGTGTGG
GTGCGTGGGGTGAGGGGTCCAGCGTGTGGTGGTGTGCGTATGTGTGTGTGAGGCGCGCGG
GGTGGATGCGTTGGTTCGGCGTCGATCATGTGATGATGCGTGCAGCGTGGTGGGTTGTAGTG
TTGTGGTGTGAGTA
```

Quality: High quality sequence stops at base: 423

Entry Created: Apr 26 1996  
Last Updated: Oct 2 1997

**COMMENTS**

This clone is available royalty-free through LLNL ; contact the IMAGE Consortium ([info@image.llnl.gov](mailto:info@image.llnl.gov)) for further information.  
MGI: 208901

**LIBRARY**

Lib Name: Soares mouse p3NMF19.5  
Organism: Mus musculus  
Develop. stage: 19.5 dpc total fetus  
Lab host: DH10B (ampicillin resistant)  
Vector: pT7T3D (Pharmacia) with a modified polylinker  
R. Site 1: Not I  
R. Site 2: Eco RI  
Description: 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' TGTTACCAATCTGAAGTGGGAGCGGCCGCGCATTTTTTTTTTTTTTTTTTTT 3'], double-stranded cDNA was size selected, ligated to Eco RI adapters (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pT7T3 vector (Pharmacia). Library went through one round of normalization to a Cot = 5. Library constructed by Bento Soares and M.Fatima Bonaldo. RNA was kindly provided by Dr. Minoru Ko (Wayne State University).

**SUBMITTER**

Name: Marra M/Mouse EST Project  
Lab: WashU-HHMI Mouse EST Project  
Institution: Washington University School of MedicineP  
Address: 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
E-mail: mouseest@watson.wustl.edu

**CITATIONS**

Title: The WashU-HHMI Mouse EST Project  
Authors: Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T., Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M., Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B., Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R., Waterston,R.  
Year: 1996  
Status: Unpublished

**MAP DATA**

---

Revised: October 24, 2001.

[Disclaimer](#) | [Write to the Help Desk](#)  
[NCBI](#) | [NLM](#) | [NIH](#)

(FILE 'HOME' ENTERED AT 18:46:23 ON 03 MAY 2002)

FILE 'MEDLINE, BIOSIS, CANCERLIT, LIFESCI, BIOTECHDS' ENTERED AT  
19:22:58

ON 03 MAY 2002

L1	241975	S	LYMPH(W)NODE#
L2	1812	S	HOMING(W)RECEPTOR#
L3	693	S	L1(S)L2
L4	156453	S	(DRUG# OR MULTIDRUG) (A) (RESISTAN?)
L5	0	S	L3(S)L4
L6	9	S	SERPIN(S)L4
L7	9	S	L6 AND PY<2001
L8	3	DUP REM	L7 (6 DUPLICATES REMOVED)
L9	3378	S	EMT6 OR (EMT-6)
L10	498	S	L9 AND SARCOMA
L11	37	S	L9 AND PY<1975
L12	29	DUP REM	L11 (8 DUPLICATES REMOVED)
L13	188	S	L9 AND (DRUG# OR MULTIDRUG) (A) RESISTAN?
L14	681	S	L9 AND HUMAN
L15	503	S	L9(S)HUMAN
L16	67	S	L15 AND L13
L17	60	S	L16 AND PY<2000
L18	26	DUP REM	L17 (34 DUPLICATES REMOVED)



PAB,EPAB,DWPI

(semaphorin or (B adj 94) or (mel adj 14) or (mel-14) or 24p3 or  
proliferin or maspin ) and (((drug or multidrug) adj  
resistan\$2)

S6494

JPAB,EPAB,DWPI

semaphorin or (B adj 94) or (mel adj 14) or (mel-14) or 24p3 or proliferin  
or maspin

S6493

USPT

((semaphorin or (B adj 94) or (mel adj 14) or (mel-14) or 24p3 or  
proliferin or maspin )with (((drug or multidrug) adj  
resistan\$2) ) and @ad<19990131

S6492

USPT

(semaphorin or (B adj 94) or (mel adj 14) or (mel-14) or 24p3 or  
proliferin or maspin ) with (((drug or multidrug) adj  
resistan\$2)

S6491

USPT

semaphorin or (B adj 94) or (mel adj 14) or (mel-14) or 24p3 or proliferin  
or maspin

S6490

JPAB,EPAB,DWPI

(((((screen\$3 or assay\$3) with ((test adj compounds\$1) or agent\$1 or  
molecule\$1) )and (((drug or multidrug) adj  
resistan\$2) )not us[pc] ) and @pd<19990131

S6489

JPAB,EPAB,DWPI

((((screen\$3 or assay\$3) with ((test adj compounds\$1) or agent\$1 or  
molecule\$1) )and (((drug or multidrug) adj  
resistan\$2) ) not us[pc]

S6488

JPAB,EPAB,DWPI

((screen\$3 or assay\$3) with ((test adj compounds\$1) or agent\$1 or  
molecule\$1) ) and (((drug or multidrug) adj

resistan\$2)

S6487

JPAB,EPAB,DWPI

(screen\$3 or assay\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1)

S6486

USPT

(((((screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1)  
 )with ((drug or multidrug) adj resistanc\$2) )and  
 @pradL54 )or (((screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1) )with ((drug or multidrug) adj  
 resistanc\$2) )and @adL53 )) not ((((((method\$1 or assay\$1) with ((test adj compounds\$1) or agent\$1 or molecule\$1)  
 )with ((drug or multidrug) adj resistanc\$2) )with (modulat\$3 or decreas\$3 or inhibit\$3 or downregulat\$3 or  
 antagoniz\$3) )and @pradL49 )or ((((((method\$1 or assay\$1) with ((test adj compounds\$1) or agent\$1 or molecule\$1) )with ((drug or multidrug) adj resistanc\$2) )with (modulat\$3 or decreas\$3 or inhibit\$3 or downregulat\$3 or antagoniz\$3) )and @adL48 ))

S6485

USPT

(((((screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1)  
 )with ((drug or multidrug) adj resistanc\$2) )and  
 @pradL54 ) or (((screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1) )with ((drug or multidrug) adj  
 resistanc\$2) )and @adL53 )

S6484

USPT

((((screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1)  
 )with ((drug or multidrug) adj resistanc\$2) ) and  
 @prad<19990131

S6483

USPT

((((screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1)  
 )with ((drug or multidrug) adj resistanc\$2) ) and  
 @ad<19990131

S6482

USPT

((screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1) )  
with ((drug or multidrug) adj resistanc\$2)

S6481

USPT

(screen\$3) with ((test adj compounds\$1) or agent\$1 or molecule\$1)

L28 ANSWER 33 OF 39 MEDLINE DUPLICATE 26  
 ACCESSION NUMBER: 87248074 MEDLINE  
 DOCUMENT NUMBER: 87248074 PubMed ID: 3596242  
 TITLE: Relationship between mitogen-regulated protein (MRP) and  
**proliferin** (PLF), a member of the prolactin/growth  
 hormone family.  
 AUTHOR: Nilsen-Hamilton M; Hamilton R T; Alvarez-Azaustre E  
 CONTRACT NUMBER: CA39256 (NCI)  
 SOURCE: GENE, (1987) 51 (2-3) 163-70.  
 Journal code: FOP; 7706761. ISSN: 0378-1119.  
 PUB. COUNTRY: Netherlands  
 Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 198707  
 ENTRY DATE: Entered STN: 19900305  
 Last Updated on STN: 19970203  
 Entered Medline: 19870724

AB Mitogen-regulated protein (MRP) is a glycoprotein secreted by Swiss  
 murine  
 3T3 cells whose levels are increased 63-fold or more over the controls by  
 growth factors. The sequence of a 226-bp MRP cDNA clone showed that a  
 region close to the C terminus of MRP is identical to a sequence found in  
 the cDNA-encoding proliferin (PLF). PLF, cloned from Balb/c 3T3 cells, is  
 a member of the prolactin/growth-hormone family. Here we show that MRP  
 and  
 PLF are also antigenically identical. Antiserum raised against purified  
 MRP specifically immunoprecipitated PLF secreted by CV-1 cells that had  
 been transfected with PLF cDNA in an SV40 vector. Also, fibroblast growth  
 factor (FGF) specifically increased the amount of PLF poly(A)+ RNA in  
 Swiss 3T3 cells. We have previously shown that FGF increases the amount  
 of  
 MRP and MRP mRNA synthesized by the same cells. The anti-MRP antiserum  
 recognized both unglycosylated and glycosylated forms of MRP and PLF. The  
 unglycosylated and glycosylated forms of PLF had the same Mr values as  
 those of the unglycosylated (21,500) and glycosylated (34,000) forms of  
 MRP. However, the anti-MRP antiserum did not recognize mouse prolactin  
 and  
 anti-mouse prolactin antibody did not recognize MRP. Evidently, MRP/PLF  
 is  
 an immunologically distinct member of the prolactin/growth-hormone family  
 of secreted, intercellular regulators.

L28 ANSWER 34 OF 39 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

L18 ANSWER 18 OF 26

MEDLINE

DUPLICATE 14

ACCESSION NUMBER: 92153685 MEDLINE

DOCUMENT NUMBER: 92153685 PubMed ID: 1346747

TITLE: Differential recognition of mdrla and mdrlb gene products in **multidrug resistant** mouse tumour cell lines by different monoclonal antibodies.

AUTHOR: Barrand M A; Twentyman P R

CORPORATE SOURCE: MRC Clinical Oncology and Radiotherapeutics Unit, Cambridge, UK.

SOURCE: BRITISH JOURNAL OF CANCER, (1992 Feb) 65 (2) 239-45.

Journal code: AV4; 0370635. ISSN: 0007-0920.

PUB. COUNTRY: ENGLAND: United Kingdom

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199203

ENTRY DATE: Entered STN: 19920410

Last Updated on STN: 19970203

Entered Medline: 19920324.

AB An immunocytochemical method was used to test the reactivity of the anti-P-glycoprotein antibodies, C219, MRK 16, JSB-1 and 265/F4 against **multidrug resistant** (MDR) variants derived from the **human** small cell lung carcinoma line, NCI-H69, the mouse fibrosarcoma line, RIF-1 and the mouse mammary tumour cell line, **EMT6**. C219 produced positive staining in MDR variants of both **human** and mouse tumour cell lines. MRK 16 and JSB-1 however recognised P-glycoprotein only in the **human** MDR cell lines and not in the mouse MDR cells. 265/F4 appeared the most selective of the monoclonal antibodies used, producing positive staining of MDR variants derived from the RIF-1 line, but not of MDR variants derived from the **EMT6** line. Total RNA was prepared from the mouse cell lines and, following reverse transcription, cDNA sequences were amplified by the polymerase chain reaction with primers specific for either the murine mdrla or the mdrlb genes. From this it was possible to show that only the mdrla gene is overexpressed in the resistant **EMT6** lines that do not stain with 265/F4 whereas both mdrla and mdrlb are overexpressed in the positively staining resistant fibrosarcoma line, RIF/1.0. Low level expression of mdrlb was detected in the sensitive parent RIF-1 cells and increasing levels of expression correlated with increasing resistance in the lines, RIF/0.1, 0.2, 0.4 and 1.0. Expression of mdrla was found only in the more resistant fibrosarcoma cell lines. It seems that 265/F4 recognises only the mdrlb P-glycoprotein. Western blotting confirmed that this antibody detects a 170 kDa protein only in membranes derived from the

resistant fibrosarcoma cells. 265/F4 may thus be used to distinguish between the murine P-glycoprotein isoforms so revealing differences between tumour cell lines in cellular localisation and in the time of appearance of mdrla and mdrlb P-glycoprotein following drug exposure.

L7 ANSWER 39 OF 141 CANCERLIT

ACCESSION NUMBER: 1998640215 CANCERLIT

DOCUMENT NUMBER: 98640215

TITLE: Diverse effects of tumor necrosis factor alpha on expression of the **multidrug resistance** -associated genes LRP and **MRP** (Meeting abstract).

AUTHOR: Stein U; Walther W; Laurencot C M; Scheffer G L; Scheper R J; Shoemaker R H

CORPORATE SOURCE: Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany 13122.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A3215.  
ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199803

AB It has previously been shown that treatment of multidrug resistant human tumor cells with cytokines can result in their sensitization towards drugs. Recently, we have reported that in vitro treatment of colon carcinoma cells with human tumor necrosis factor alpha (TNF) or transduction of the human TNF gene is associated with reduced expression of the mdrl gene at the mRNA, protein and functional level. To

investigate

this phenomenon in relation to the more recently described MDR-associated genes LRP (lung resistance protein) and MRP (multidrug resistance associated protein), we evaluated the effect of TNF on the mRNA level by RT-PCR and on the protein level by immuno flow cytometry. Human colon carcinoma cell lines HCT15 and HCT116 were incubated with TNF for 2, 12, 24, 48 or 72 hours, or were transduced with the human TNF gene.

**Modulated** expression of LRP and MRP was observed under both

treatment conditions: LRP expression was reduced by TNF in an apparently time- and dose-related fashion. In contrast, MRP expression was increased on both expression levels. These results illustrate the complexity of multiple MDR phenotypes, which may coexist within a tumor cell

population.

They further suggest that strategies for **reversal** of MDR should not focus exclusively on the mdrl gene, but should also address the net effect of MDR mechanisms which may respond in coordinate, or contrasting ways to **modulating** agents.

L7 ANSWER 49 OF 141 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1997:517083 BIOSIS

DOCUMENT NUMBER: PREV199799816286

TITLE: Altered expression of the genes regulating apoptosis in  
**multidrug resistant** human myeloid  
leukemia cell lines overexpressing MDR1 or **MRP**  
gene.

AUTHOR(S): Kim, Choong H.; Gollapudi, Sastry; Lee, Thomas; Gupta,  
Sudhir

CORPORATE SOURCE: Med. Sci. I, C-240 Univ. Calif., Irvine, CA 92697-4069 USA

SOURCE: International Journal of Oncology, (1997) Vol. 11, No. 5,  
pp. 945-950.

ISSN: 1019-6439.

DOCUMENT TYPE: Article

LANGUAGE: English

AB Development of multidrug resistance (MDR) in cancer cells is associated  
with an overexpression of ATP-binding cassette proteins (e.g.  
P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP)) and  
with **decreased** chemotherapeutic agent-induced apoptosis. In this  
study, we investigated whether MDR in cancer cells was associated with  
altered expression of genes regulating apoptosis using a drug sensitive  
human myeloid leukemia cell line (HL60), and its MDR sublines,  
overexpressing MRP (HL60/AR) or P-gp (HL60/taxol). Expression of  
apoptotic

genes was examined at the protein level by flow cytometry and at the mRNA  
level by **reverse** transcriptase-polymerase chain reaction  
(RT-PCR). We observed that the MDR cells either did not express or  
expressed a reduced level of the apoptosis promoters Fas, Bcl-x-s, and  
Bax, whereas expression of the apoptosis repressor Bcl-x-L was increased.  
Both vincristine and anti-Fas monoclonal antibody induced apoptosis in  
HL60 cells but failed to do so in both MDR cell lines. These data suggest  
that acquired MDR in cancer cells, regardless of the type of  
overexpressed

ABC transporter, may be associated with increased expression of  
antiapoptotic genes and **decreased** expression of pro-apoptotic  
genes.

*order*

L7 ANSWER 47 OF 141 MEDLINE DUPLICATE 28  
ACCESSION NUMBER: 1998019056 MEDLINE  
DOCUMENT NUMBER: 98019056 PubMed ID: 9358024  
TITLE: Retrovirus-mediated gene transfer of the **multidrug resistance**-associated protein (MRP) cDNA protects cells from chemotherapeutic agents.  
AUTHOR: D'Hondt V; Caruso M; Bank A  
CORPORATE SOURCE: Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA.  
SOURCE: HUMAN GENE THERAPY, (1997 Oct 10) 8 (15) 1745-51.  
Journal code: A12; 9008950. ISSN: 1043-0342.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199802  
ENTRY DATE: Entered STN: 19980217  
Last Updated on STN: 19980217  
Entered Medline: 19980203

AB Transduction of hematopoietic progenitors with a multidrug resistance gene

like mdr-1 or mrp aims to protect bone marrow from toxicity of chemotherapeutic agents. The interest in the use of mrp as an alternative to mdr-1 gene transfer for bone marrow protection lies in its different **modulation**. Indeed, classical P-gp **reversal** agents, tested in the clinic to **decrease** mdr-1 tumor resistance, have little or no effect on MRP function. This would allow, in the same patient, the use of **reversal** agents to **decrease** P-gp tumor resistance without **reversing** bone marrow protection of the transduced hematopoietic cells provided by multidrug resistance-associated

protein (MRP). As a first step, we have constructed and tested two different mrp-containing vectors with either the Harvey retroviral long terminal repeat (LTR) or PGK as promoters and generated ecotropic producer

cells. We have shown by Southern blot analysis that retroviral supernatant

from these producer cells can efficiently transmit the mrp gene to target cells. Mrp expression could be detected by fluorescence-activated cell sorting (FACS) analysis in the producer cells. The transduced cells have increased resistance to doxorubicin, vincristine, and etoposide. Furthermore, chemoprotection of the transduced cells was increased after selection with chemotherapeutic agents in the presence of glutathione, a co-factor for MRP function. These data indicate that mrp retroviral vectors may be useful for chemoprotection and selection.

*motivation for upregulation*



L7 ANSWER 45 OF 141 CANCERLIT

ACCESSION NUMBER: 1998639569 CANCERLIT

DOCUMENT NUMBER: 98639569

TITLE: Chemoprotection by retroviral gene transfer of the  
**multidrug resistance**-associated protein (  
**MRP**) cDNA (Meeting abstract).

AUTHOR: D'Hondt V; Machiels J P; Caruso M; Bank A; Symann M

CORPORATE SOURCE: Universite Catholique de Louvain, Brussels, Belgium 1200.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol.

38, pp. A2569.

ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199801

AB The interest in the use of MRP as an alternative to mdr-1 gene transfer for bone marrow protection lies in its different **modulation**. Classical P-gp **reversal** agents, tested in clinic to **decrease** mdr-1 tumor resistance, have little or no effect on MRP function. This would allow, in the same patient, the use of **reversal** agents to **decrease** mdr-1 tumor resistance without **reversing** bone marrow protection of the transduced hematopoietic cells provided by MRP. We have constructed two MRP-containing retroviral vectors and generated producer cells and have shown by Southern blot analysis that retroviral supernatant from these producer cells can efficiently transmit the MRP gene to target cells. MRP expression was detected by FACS analysis in the producer cells as in the transduced cells, conferring multidrug resistance to both. Furthermore, selection of transduced cells in chemotherapeutic drug was achieved.

These

data indicate that MRP retroviral vectors have a potential application for

bone marrow chemoprotection. We are now developing a murine and an in vitro human model to test this hypothesis.

L7 ANSWER 63 OF 141 CANCERLIT

ACCESSION NUMBER: 97619095 CANCERLIT

DOCUMENT NUMBER: 97619095

TITLE: Role of **multidrug resistance** protein (**MRP**)-mediated transport of chlorambucil and melphalan conjugated to glutathione in **drug resistance** (Meeting abstract).

AUTHOR: Barnouin K; Leier I; Jedlitschky G; Pourtier-Manzanedo A; Konig J; Keppler D

CORPORATE SOURCE: Division of Tumor Biochemistry, Deutsches Krebsforschungszentrum, D-69120 Heidelberg, Germany.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A408.

ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199709

AB The human multidrug resistance protein (MRP) confers resistance to a number of different cytostatic drugs and functions as an export pump for glutathione S-conjugates, glucuronides, and other amphiphilic anions. The present study details for the first time MRP-mediated ATP-dependent transport of various glutathione S-conjugates of the alkylating agents chlorambucil and melphalan. In membrane vesicles from MRP-transfected

HeLa

cells transport rates of the conjugates **decreased** in the following order: monogluthionyl chlorambucil, digluthionyl chlorambucil, and monohydroxy monogluthionyl chlorambucil; and monogluthionyl melphalan and monohydroxy monogluthionyl melphalan. Immunoblotting with a polyclonal antibody directed against the carboxyl-terminal sequence of human MRP indicated the presence of the hamster homolog of MRP in the membranes of normal and glutathione transferase alpha-overexpressing chlorambucil-resistant Chinese Hamster Ovary (CHO) cells. This was confirmed by amplification and sequencing of

a

fragment of hamster mrp cDNA. In membrane vesicles prepared from both CHO cell lines we observed ATP-dependent transport of monogluthionyl chlorambucil and of the glutathione S-conjugate leukotriene C4, a high-affinity substrate of MRP. Comparison of chlorambucil cytotoxicity

in

a number of MRP-overexpressing and parental cells, as well as in chlorambucil-resistant and control CHO cells, demonstrated that MRP expression alone is not sufficient to confer resistance to the alkylating drug and that its conjugation to glutathione is of additional importance.

L7 ANSWER 64 OF 141 MEDLINE

DUPLICATE 37

L7 ANSWER 73 OF 141 BIOTECHDS COPYRIGHT 2002 THOMSON DERWENT AND ISI  
ACCESSION NUMBER: 1996-04511 BIOTECHDS

TITLE: **Multidrug-resistance** protein MRP  
and DNA encoding it;  
recombinant multidrug-resistance-associated protein  
production using new vector and sense and antisense DNA  
sequence potential application in small cell lung  
carcinoma gene therapy

AUTHOR: Deerley R G; Cole S P C

PATENT ASSIGNEE: Univ.Kingston-Queen's

LOCATION: Kingston, Canada.

PATENT INFO: US 5489519 **6 Feb 1996**

APPLICATION INFO: US 1993-141893 26 Oct 1993

PRIORITY INFO: US 1993-141893 26 Oct 1993

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 1996-115615 [12]

AN 1996-04511 BIOTECHDS

AB An isolated nucleic acid (I) comprising a nucleotide sequence encoding a multidrug-resistance-associated protein (MRP) having at least 70% homology to the protein sequence disclosed is claimed. The MRP is resistant to doxorubicin, on a drug-sensitive mammal cell when the protein is expressed in the cell and the resistance is not **reversed** by chemosensitizers which **reverse** P-glycoprotein-mediated multidrug-resistance. Also claimed are: a naturally-occurring nucleic acid which hybridizes under stringent conditions to (I) and encodes a protein having activity of the MRP with at least 60% homology to the disclosed protein sequence; isolated

nucleic

acid conferring multidrug-resistance on a cell; antisense (I); a recombinant expression vector containing (I); a transformed host; preparation of a MRP involving culturing a transformant in suitable medium and recovering the product; and a diagnostic kit for multidrug-resistant tumor cells comprising a DNA probe complementary to (I). The sense and antisense nucleic acid can be used in small cell

lung

carcinoma gene therapy, especially following chemotherapy. (49pp)

L7 ANSWER 74 OF 141 CANCERLIT

L7 ANSWER 19 OF 141 MEDLINE

DUPLICATE 14

ACCESSION NUMBER: 1999120323 MEDLINE

DOCUMENT NUMBER: 99120323 PubMed ID: 9923448

TITLE: Selectively induced high **MRP** gene expression in **multidrug-resistant** human HL60 leukemia cells.

AUTHOR: Wada H; Saikawa Y; Niida Y; Nishimura R; Noguchi T; Matsukawa H; Ichihara T; Koizumi S

CORPORATE SOURCE: Department of Pediatrics, Kanazawa University School of Medicine, Japan.

SOURCE: EXPERIMENTAL HEMATOLOGY, (1999 Jan) 27 (1) 99-109.

Journal code: EPR; 0402313. ISSN: 0301-472X.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199902

ENTRY DATE: Entered STN: 19990311

Last Updated on STN: 19990311

Entered Medline: 19990225

AB A subclone HL60/DOX was selected from a human leukemic HL60 cell line for resistance to doxorubicin (DOX) by exposure to stepwise increasing concentrations of the drug and coexposure to a potential P-glycoprotein (P-gp) inhibitor, cepharanthine (a biscoclaurine alkaloid). Compared with the parent HL60 cells, the HL60/DOX cells were 13.0-fold more resistant

to

DOX and showed multidrug-resistant (MDR) phenotype characterized by 4.6-fold, 2.3-fold, and 5.7-fold cross-resistance to vincristine, pirarubicin, and etoposide, respectively, but no cross-resistance to alkylating agent, cisplatin. Immunocytochemical analyses using the specific monoclonal antibody, MRP1, and quantitative analyses using a competitive **reverse** transcription-polymerase chain reaction (CRT-PCR) confirmed overexpression of MRP gene products (about 8-fold determined by CRT-PCR) in this resistant clone. The P-gp expression was not detectable by the monoclonal antibody, C219, in the HL60/DOX cells, and that was consistent with extremely low levels of *mdr1* mRNA expression determined by CRT-PCR in this clone. Drug accumulation and efflux studies demonstrated the significantly increased efflux rate of DOX compared to the parent HL60 cells. This enhancement of DOX efflux was **reversed** by the addition of 10 microM verapamil. To investigate the additional underlying mechanisms contributing to MDR phenotype in the HL60/DOX

cells,

the levels of DNA topoisomerases (Topo) including Topo I, Topo IIalpha, and Topo IIbeta, and gamma-glutamylcystein synthetase ( $\gamma$ -GCS) expression were determined using CRT-PCR techniques. Normal expression of each

enzyme

at the transcriptional level was demonstrated in this resistant clone. Southern blot analysis of the gene organization in the HL60/DOX cells revealed the amplification of MRP gene. These results indicate that alteration of the drug accumulation from enhanced efflux appears to be a major mechanism(s) of MDR phenotype and attributable to high levels of

MRP

expression in the HL60/DOX cells. Overexpression of MRP in this clone is regulated by the genomic amplification of DNA and increased levels of the MRP mRNA, independently with the normal expression of Topo I, Topo IIalpha, Topo IIbeta, or gamma-GCS.

L7 ANSWER 140 OF 141 CANCERLIT

ACCESSION NUMBER: 95612433 CANCERLIT

DOCUMENT NUMBER: 95612433

TITLE: ATP-dependent glutathione conjugate transport in HL60 cells

overexpressing the **multidrug resistance** associated protein (**MRP**) (Meeting abstract).

AUTHOR: Jedlitschky G; Leier I; Buchholz U; Barnouin K; Center M; Keppler D

CORPORATE SOURCE: Division of Tumor Biochemistry, Deutsches Krebsforschungszentrum, 69120 Heidelberg, Germany.

SOURCE: Anticancer Drugs, (1994). Vol. 5, Suppl. 1, pp. 4.

ISSN: 0959-4973.

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199510

AB ATP-dependent transport of the glutathione conjugate leukotriene C4 (LTC4)

was studied in membrane vesicles from the human leukemia cell line HL60 and a subline isolated for resistance to adriamycin (HL60/ADR) which was shown to overexpress a 190-kD glycoprotein encoded by the MRP gene. The function of this ATP-binding protein, which has a limited sequence similarity with P-glycoproteins, is so far unknown. The rate of ATP-dependent LTC4 transport observed in membrane vesicles prepared from the HL60/ADR cells was more than 25-fold higher than in membrane vesicles from parent HL60 cells (25 pmol x mg protein-1 x min-1 vs less than 1

pmol x mg protein-1 x min-1). In photoaffinity labeling studies with these membranes a LTC4-binding protein of about 190 kD was detected only in the HL60/ADR membranes. The quinoline-based leukotriene receptor **antagonist** MK 571 completely inhibited the ATP-dependent LTC4 transport by HL60/ADR membrane vesicles at a concentration of 5 uM. The [3H]LTC4 labeling of the 190 kD glycoprotein was also competed for by

this transport inhibitor. These data indicate that P-gp-independent, pl90-mediated multidrug resistance is associated with an enhanced ATP-dependent transport of glutathione conjugates.

L7 ANSWER 141 OF 141 CANCERLIT

L7 ANSWER 139 OF 141 CANCERLIT

ACCESSION NUMBER: 95612480 CANCERLIT

DOCUMENT NUMBER: 95612480

TITLE: **Reversal of drug resistance**  
in **MRP** overexpressing **multidrug**  
**resistant** human lung tumor cells (Meeting  
abstract).

AUTHOR: Versantvoort C H; Broxterman H J; Bagrij T; Twentyman P R

CORPORATE SOURCE: MRC Clinical Oncology and Radiotherapeutics Unit, Hills  
Road, Cambridge CB2 2QH, UK.

SOURCE: Anticancer Drugs, (1994). Vol. 5, Suppl. 1, pp.  
30.

ISSN: 0959-4973.

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199510

AB A number of multidrug resistant (MDR) tumor cell lines, which do not overexpress P-glycoprotein, have now been reported to overexpress the MRP gene. In most of these MRP overexpressing resistant cell lines the accumulation of drugs is **decreased** as a result of an enhanced drug efflux. In this study, we examined the effects of buthionine sulfoximine (BSO), an inhibitor of glutathione synthesis, on drug resistance and cellular drug accumulation in two, doxorubicin-selected, MRP overexpressing, MDR human lung cancer cell lines. The COR-L23/R cells were 21-, 32- and 21-fold resistant to daunorubicin, vincristine and rhodamine 123, respectively, as measured in a 5-day MTT assay. Pretreatment of the resistant cells with BSO (25 uM, 20 h) enhanced the toxicity of the drugs 10-, 18- and 18-fold. Moreover, pretreatment of the resistant cells with BSO increased the cellular accumulation and retention

of daunorubicin and rhodamine up to the level of the parental COR-L23/P cells, while having no effect on the parental cells. In another MRP overexpressing MDR cell line, GLC4/ADR, **reversal** of daunorubicin toxicity by BSO was also associated with a complete **reversal** of the accumulation deficit. Total glutathione content was lower in the COR-L23/R cells than in the parental cells 11.2 and 18.6 nmol/10(6)

cells,  
respectively. However, in the GLC4/ADR cells the glutathione content was higher than in the GLC4 cells, 9.5 vs 5.1 nmol/10(6) cells. The glutathione content was reduced by exposure to BSO: 2- to 3-fold in the CORL23 cell lines and 3- to 5-fold in the GLC4 cell lines. When intermediate levels of glutathione (40-70% of control) were obtained, only

a partial **reversal** of the daunorubicin accumulation deficit was measured in the resistant cells. Thus, BSO enhances the toxicity of drugs in the MRP overexpressing MDR cells by inhibition of the enhanced efflux. The possible involvement of cellular glutathione in drug transport in MRP overexpressing MDR cell lines is currently being investigated.

L7 ANSWER 140 OF 141 CANCERLIT

L7 ANSWER 129 OF 141 MEDLINE DUPLICATE 74  
ACCESSION NUMBER: 95118326 MEDLINE  
DOCUMENT NUMBER: 95118326 PubMed ID: 7818510  
TITLE: The specific bisindolylmaleimide PKC-inhibitor GF 109203X  
efficiently **modulates** MRP-associated  
multiple **drug resistance**.  
AUTHOR: Gekeler V; Boer R; Ise W; Sanders K H; Schachtele C; Beck  
J  
CORPORATE SOURCE: Byk Gulden, Konstanz, Germany.  
SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,  
(1995 Jan 5) 206 (1) 119-26.  
Journal code: 9Y8; 0372516. ISSN: 0006-291X.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199502  
ENTRY DATE: Entered STN: 19950217  
Last Updated on STN: 19990129  
Entered Medline: 19950209

AB The newly identified drug transporter MRP is functionally linked to a  
multiple drug resistance independent from P-glycoprotein. Resistance  
modifiers for this type of MDR are rare at present. We analyzed the  
**modulating** effect of the highly selective bisindolylmaleimide PKC  
inhibitor GF 109203X on the MRP overexpressing human MDR sublines HL60/AR  
and GLC4/ADR. Applying a 72 hour MTT-assay we demonstrate a complete  
**reversal** of the vincristine resistance of HL60/AR cells.  
Adriamycin resistance of HL60/AR, or vincristine resistance of GLC4/ADR  
were partially **reversed**. Furthermore, rhodamine 123 efflux from  
HL60/AR was strongly **modulated** by GF 109203X. Since the PKC  
inhibitor did not significantly influence MRP gene expression at the mRNA  
level which was examined by cDNA-PCR, our results suggest either a direct  
interaction of the compound with MRP or/and an indirect influence on MRP  
activity via altering the phosphorylation status of the transporter.

L7 ANSWER 130 OF 141 MEDLINE DUPLICATE 7

L7 ANSWER 128 OF 141 MEDLINE

DUPLICATE 73

ACCESSION NUMBER: 96034538 MEDLINE

DOCUMENT NUMBER: 96034538 PubMed ID: 8534927

TITLE: Difloxacin **reverses multidrug resistance** in HL-60/AR cells that overexpress the **multidrug resistance**-related protein (MRP) gene.

AUTHOR: Gollapudi S; Thadepalli F; Kim C H; Gupta S

CORPORATE SOURCE: Division of Basic and Clinical Immunology, University of California, Irvine 92717, USA.

SOURCE: ONCOLOGY RESEARCH, (1995) 7 (5) 213-25.

Journal code: BBN; 9208097. ISSN: 0965-0407.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199602

ENTRY DATE: Entered STN: 19960221

Last Updated on STN: 19970203

Entered Medline: 19960208

AB In this study, we have examined the in vitro chemosensitizing activity of difloxacin, a quinolone antimicrobial agent, in the multidrug-resistant human myeloid leukemia HL-60/AR cell line. HL-60/AR cells were found to overexpress multidrug resistance-associated protein (MRP) mRNA as compared

to HL-60 cells. Difloxacin, in a concentration-dependent manner, increased

the sensitivity of HL-60/AR cells to daunorubicin, adriamycin, and vincristine, and partially corrected the altered drug transport. In addition, difloxacin corrected subcellular distribution of adriamycin by inducing redistribution of the drug from the perinuclear region to the nucleus in HL-60/AR cells. The chemosensitizing effect of difloxacin was observed at clinically achievable concentrations. We conclude that difloxacin is an effective chemosensitizer of MRP-associated multidrug-resistant tumor cells and is a potential candidate for clinical use to **reverse** multidrug resistance.



L7 ANSWER 126 OF 141 MEDLINE

DUPLICATE 72

ACCESSION NUMBER: 95272127 MEDLINE

DOCUMENT NUMBER: 95272127 PubMed ID: 7752673

TITLE: **Drug resistance** mechanisms and  
**MRP** expression in response to epirubicin treatment  
in a human leukaemia cell line.

AUTHOR: Davey R A; Longhurst T J; Davey M W; Belov L; Harvie R M;  
Hancox D; Wheeler H

CORPORATE SOURCE: Bill Walsh Cancer Research Laboratories, Department of  
Clinical Oncology, Royal North Shore Hospital, St.  
Leonards, Australia.

SOURCE: LEUKEMIA RESEARCH, (1995 Apr) 19 (4) 275-82.  
Journal code: K9M; 7706787. ISSN: 0145-2126.

PUB. COUNTRY: ENGLAND: United Kingdom  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199506

ENTRY DATE: Entered STN: 19950629

Last Updated on STN: 19950629

Entered Medline: 19950622

AB A drug resistant series of sublines were developed by treating the human leukaemia CCRF-CEM cell line with 16-1000 ng/ml of the anthracycline, epirubicin. The sublines developed resistance in two stages, neither involving detectable levels of P-glycoprotein. Treatment with up to 50 ng/ml epirubicin produced sublines with cross resistance limited to the anthracyclines and etoposide. Treatment with 100-1000 ng/ml epirubicin produced sublines with increased expression of the mrp gene, increased resistance to the anthracyclines and etoposide, additional cross resistance to vincristine and colchicine, **decreased** drug accumulation and **reversal** of resistance by verapamil and by buthionine sulfoximine (BSO; an inhibitor of glutathione synthesis). Our results indicate an interaction between MRP and glutathione metabolism as a mechanism for multidrug resistance.

L7 ANSWER 124 OF 141 MEDLINE DUPLICATE 70

ACCESSION NUMBER: 95194429 MEDLINE

DOCUMENT NUMBER: 95194429 PubMed ID: 7887949

TITLE: The leukotriene LTD4 receptor **antagonist** MK571 specifically **modulates** MRP associated **multidrug resistance**.

AUTHOR: Gekeler V; Ise W; Sanders K H; Ulrich W R; Beck J

CORPORATE SOURCE: Byk Gulden, Konstanz, Germany.

SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1995 Mar 8) 208 (1) 345-52.  
Journal code: 9Y8; 0372516. ISSN: 0006-291X.

PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199504

ENTRY DATE: Entered STN: 19950425  
Last Updated on STN: 19970203  
Entered Medline: 19950413

AB The multidrug resistant cell lines HL60/AR and GLC4/ADR show high overexpression of the gene encoding the multidrug resistance associated protein MRP compared to their drug sensitive parental counterparts. This and the virtual absence of mdrl/P-glycoprotein gene expression was proven by a complementary DNA polymerase chain reaction (cDNA-PCR) approach. Applying a 72-hour tetrazolium based colorimetric MTT-assay we demonstrate

on both MDR sublines a dose-dependent **modulation** of drug resistances by the leukotriene LTD4 receptor **antagonist** MK571. A complete **reversal** of vincristine resistances was achieved at final MK571 concentrations of 30 microM (HL60/AR) or 50 microM (GLC4/ADR) which by itself did not disturb cellular proliferation. The drug resistance of a mdrl/P-gp overexpressing multidrug-resistant HL60 subline, in contrast, was not significantly affected by MK571. Similar effects were seen using the glutathione (GSH) synthesis inhibitor buthionine sulfoximine (BSO). Our results point to a relationship between MRP and a conjugate transporter and identify MK571 as a new tool structure for developing **modulators** specific for a MRP associated multidrug resistance.

L7 ANSWER 122 OF 141 MEDLINE

DUPLICATE 68

ACCESSION NUMBER: 95367497 MEDLINE

DOCUMENT NUMBER: 95367497 PubMed ID: 7640227

TITLE: Chemosensitisation of spontaneous **multidrug resistance** by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing **MRP** or **MDR1**.

AUTHOR: Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M

CORPORATE SOURCE: Department of Biochemistry, Kyushu University School of Medicine, Fukuoka, Japan.

SOURCE: BRITISH JOURNAL OF CANCER, (1995 Aug) 72 (2) 418-23.

Journal code: AV4; 0370635. ISSN: 0007-0920.

PUB. COUNTRY: SCOTLAND: United Kingdom

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199509

ENTRY DATE: Entered STN: 19950930

Last Updated on STN: 19980206

Entered Medline: 19950921

AB Multidrug resistance phenotypes in human tumours are associated with the overexpression of the 170 kDa P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene, and also with that of the non-P-glycoprotein-mediated multidrug resistance gene, MRP, which encodes a 190 kDa membrane ATP-binding protein. We have previously reported that overexpression of MRP appears to be responsible for spontaneous multidrug resistance in

some

human glioma cell lines (Abe et al., Int. J. Cancer, 58, 860-864, 1994).

In this study, we investigated whether chemosensitising agents of P-glycoprotein-mediated multidrug resistance such as verapamil, a biscoclaurine alkaloid (cepharanthine), and a dihydropyridine analogue (NIK250) could also **reverse** multidrug resistance in human glioma cells. The glioma cell lines were the two MRP-expressing cell lines, T98G and IN500, an MDR1-expressing cell line, CCF-STTG1, and the MRP1 MDR1-non-expressing cell line, IN157. Verapamil and NIK250 almost completely **reversed** drug resistance to vincristine, etoposide and doxorubicin in T98G cells, while they also **reversed** drug resistance to vincristine and etoposide, but only partially to

doxorubicin

in IN500 cells. Cepharanthine as well as verapamil and NIK250

**reversed** vincristine resistance in CCF-STTG1 cells, but cepharanthine only partially **reversed** drug resistance in T98G and IN500 cells. The cellular accumulation of [3H]etoposide increased about 2- and 3-fold compared with control in T98G cells in the presence

of

verapamil and NIK250 respectively. Furthermore, the release of

doxorubicin

from the nuclei of T98G cells was blocked by NIK250. However, NIK250 and verapamil caused no apparent increase in vincristine accumulation in T98G cells. NIK250 or verapamil might exert inhibitory effects upon MRP function, resulting in a **reversal** of MRP-mediated spontaneous multidrug resistance in cultured human glioma cells.

L7 ANSWER 122 OF 141 MEDLINE

DUPLICATE 68

ACCESSION NUMBER: 95367497 MEDLINE

DOCUMENT NUMBER: 95367497 PubMed ID: 7640227

TITLE: Chemosensitisation of spontaneous **multidrug resistance** by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing **MRP** or **MDR1**.

AUTHOR: Abe T; Koike K; Ohga T; Kubo T; Wada M; Kohno K; Mori T; Hidaka K; Kuwano M

CORPORATE SOURCE: Department of Biochemistry, Kyushu University School of Medicine, Fukuoka, Japan.

SOURCE: BRITISH JOURNAL OF CANCER, (1995 Aug) 72 (2) 418-23.

Journal code: AV4; 0370635. ISSN: 0007-0920.

PUB. COUNTRY: SCOTLAND: United Kingdom  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199509

ENTRY DATE: Entered STN: 19950930

Last Updated on STN: 19980206

Entered Medline: 19950921

AB Multidrug resistance phenotypes in human tumours are associated with the overexpression of the 170 kDa P-glycoprotein encoded by the multidrug resistance 1 (MDR1) gene, and also with that of the non-P-glycoprotein-mediated multidrug resistance gene, MRP, which encodes a 190 kDa membrane ATP-binding protein. We have previously reported that overexpression of MRP appears to be responsible for spontaneous multidrug resistance in

some

human glioma cell lines (Abe et al., Int. J. Cancer, 58, 860-864, 1994). In this study, we investigated whether chemosensitising agents of P-glycoprotein-mediated multidrug resistance such as verapamil, a biscochlorine alkaloid (cepharanthine), and a dihydropyridine analogue (NIK250) could also **reverse** multidrug resistance in human glioma cells. The glioma cell lines were the two MRP-expressing cell lines, T98G and IN500, an MDR1-expressing cell line, CCF-STTG1, and the MRP1 MDR1-non-expressing cell line, IN157. Verapamil and NIK250 almost completely **reversed** drug resistance to vincristine, etoposide and doxorubicin in T98G cells, while they also **reversed** drug resistance to vincristine and etoposide, but only partially to doxorubicin

in IN500 cells. Cepharanthine as well as verapamil and NIK250 **reversed** vincristine resistance in CCF-STTG1 cells, but cepharanthine only partially **reversed** drug resistance in T98G and IN500 cells. The cellular accumulation of [3H]etoposide increased about 2- and 3-fold compared with control in T98G cells in the presence of

verapamil and NIK250 respectively. Furthermore, the release of doxorubicin

from the nuclei of T98G cells was blocked by NIK250. However, NIK250 and verapamil caused no apparent increase in vincristine accumulation in T98G cells. NIK250 or verapamil might exert inhibitory effects upon MRP function, resulting in a **reversal** of MRP-mediated spontaneous multidrug resistance in cultured human glioma cells.

L7 ANSWER 114 OF 141 CANCERLIT

ACCESSION NUMBER: 97609782 CANCERLIT

DOCUMENT NUMBER: 97609782

TITLE: Probenecid **reverses multidrug resistance** in tumor cells that overexpress **multidrug resistance**-related protein (MRP) gene and not in tumor cells that overexpress **multidrug resistance 1** (MDR 1) gene (Meeting abstract).

AUTHOR: Gupta S; Gollapudi S

CORPORATE SOURCE: University of California, Irvine, CA 92717.

SOURCE: Int J Oncol, (1995). Vol. 7, Suppl., pp. 987.  
ISSN: 1019-6439.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199705

AB Objective and Rationale: The development of multidrug resistance (MDR) to anticancer agents by tumor cells is a major concern to the therapeutic cure of cancer. An overexpression of MDR 1 and its product P-glycoprotein (P-gp), a member of ATP-binding cassette (ABC) transport proteins, is associated with MDR and a number of agents are available that **reverse** MDR in MDR 1 overexpressing tumor cells. However, there are MDR tumor cells that lack MDR 1 but overexpress MRP gene (another member of ABC transport protein). Currently there is a need for agents that can **reverse** MDR in tumor cell lines that overexpress MRP gene and its product. Because MRP facilitates transport of leukotriene C4 (LTC4), and probenecid is an inhibitor of LTC4, we investigated the

effect

of probenecid on drug sensitivity, drug accumulation, subcellular drug distribution and intracellular pH (pHi) in human myeloid leukemia HL60/AR MDR cell line that overexpresses MRP gene and its product. Methods: Drug sensitivity was tested by MTT assay. Intracellular accumulation of daunorubicin (DNR) and vincristine (VCR) was measured by flow cytometry and scintillation counter respectively. Intracellular pH was assessed

with

BCECF-AM dye, using FACScan. Subcellular drug distribution was analyzed with laser-based confocal microscope. Results: Probenecid, in a concentration dependent manner, **reversed** resistance to daunorubicin (DNR) and vincristine (VCR). However, probenecid had no effect on drug (DNR and VCR) accumulation, subcellular drug distribution and pHi. The concentrations of probenecid that **reversed** multidrug resistance are clinically achievable in vivo. In contrast, probenecid did not **reverse** MDR in P-gp overexpressing murine leukemia P388/ADR cell line. Conclusion: These data suggest that probenecid is an effective chemosensitizer of MRP-associated multidrug resistant tumor cells and is a potential candidate for clinical use to **reverse** MDR.

L7 ANSWER 112 OF 141 CANCERLIT

ACCESSION NUMBER: 96649455 CANCERLIT

DOCUMENT NUMBER: 96649455

TITLE: Protein kinase inhibitor-induced alterations of drug uptake

and surface antigen expression in human **multidrug**

**resistant**, Pgp and non-Pgp (**mrp**)

promyelocytic leukemia (HL-60) cells (Meeting abstract).

AUTHOR: Sedlak J; Hunakova L; Sulikova M; Pailingerova D; Chorvath B

CORPORATE SOURCE: Cancer Research Institute, SAS, Spitalska 21, SK-812 32 Bratislava, Slovak Republic.

SOURCE: Anticancer Res, (1995). Vol. 15, No. 5A, pp. 1644.

ISSN: 0250-7005.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199608

AB Protein kinase inhibitors staurosporine and CGP 41 251--a benzoylated derivative of staurosporine with selective PRC inhibitory activity, **reversed** the **decreased** daunomycine and rhodamine R123 uptake in MDR-1 (HL-60/VCR) but not in MRP (HL-60/ADR) cells. CGP 41 251 **reversed** the **decreased** daunomycin uptake in HL-60/VCR cells (with Pgp-mediated drug resistance) more efficiently (as compared

on

the equimolar basis) than staurosporine. The protein tyrosine kinase inhibitor genistein unexpectedly **modulated** the **decreased** daunomycin uptake in Pgp-positive (HL60/VCR) cells, but not in HL-60/ADM (MRP) cells. Cell surface phenotype of two HL-60 drug resistant cell sublines, ie, HL-60/VCR (MDR1) and HL-60/ADR (MRP), were compared with that of the parental, drug-sensitive HL-60 cells. Both drug-resistant

cell

lines expressed markedly **decreased** levels of cell surface HLA class I antigen in comparison with the parental, drug sensitive HL-60 cells. Interferon-gamma induced a marked HLA class I upregulation in both examined drug-resistant HL-60 cell lines and, to a lesser extent, also in their parental, drug-sensitive HL-60 cells. Both studied protein kinase inhibitors (staurosporine and CGP 41 251) exhibited variable effects on cell surface antigen (HLA, ICAM-1, CD59) expression, suggesting complex interactions between PKC-dependent and independent mechanisms in the regulation of surface antigen expression in these cell lines.

L7 ANSWER 106 OF 141 CANCERLIT

ACCESSION NUMBER: 95609981 CANCERLIT

DOCUMENT NUMBER: 95609981

TITLE: Ethoxylated fatty acids (EOFAs), active components contained in Cremophor EL, enhance daunorubicin (dnr) accumulation in P-glycoprotein (Pgp) but not **multidrug resistance**-associated protein (MRP) overexpressing cells (Meeting abstract).

AUTHOR: Tong Y; Piraner O N; Doyle L A; Cornblatt B; Chang B; Yang W; Ross D D

CORPORATE SOURCE: Univ. of Maryland Cancer Center, Baltimore, MD 21201.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1995). Vol.

36, pp. A2206.

ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199508

AB Three EOFAs were synthesized with structural similarities to active multidrug resistance (MDR) **modulating** EOFAs identified in Cremophor EL. These EOFAs were tested for their effects on dnr accumulation (1 ug/ml, 3 hr) in MDR sublines of human leukemia HL-60 cells

that overexpress Pgp (HL-60/Vinc) or MRP (HL-60/AR). In HL-60/Vinc cells, the EOFAs caused a dose-dependent enhancement of intracellular dnr content

(measured by flow cytometry), with maximal enhancement (Emax) attained at 10 ug/ml. This represents a 15- to 50-fold enhancement in potency, compared to the effects of Cremophor EL on HL60/Vinc cells. The level of intracellular dnr accumulation attained at Emax for HL60/Vinc cells was equal that of parental, drug-sensitive HL-60 cells. In contrast, concentrations of EOFAs up to 100 ug/ml produced enhancement of dnr accumulation in HL-60/AR cells that were only 20% to 50% those attained

in parental HL-60 cells. This is similar to the response to Cremophor EL in these cells, where only slight enhancement of dnr accumulation was observed. Paradoxically, HL-60/AR cells were, in general, more sensitive to the cytotoxic effects of the EOFAs than were HL-60/Vinc or HL-60 cells.

The increased potency of these EOFAs over Cremophor EL in enhancing dnr accumulation in Pgp overexpressing cells warrants further investigation

of this class of compounds as clinical **modulators** of MDR.

L7 ANSWER 107 OF 141 CANCERLIT

L7 ANSWER 103 OF 141 MEDLINE DUPLICATE 60

ACCESSION NUMBER: 97029038 MEDLINE

DOCUMENT NUMBER: 97029038 PubMed ID: 8875050

TITLE: DiOC2(3) is not a substrate for **multidrug resistance** protein (MRP)-mediated drug efflux.

AUTHOR: Minderman H; Vanhoefer U; Toth K; Yin M B; Minderman M D; Wrzosek C; Slovak M L; Rustum Y M

CORPORATE SOURCE: Department of Experimental Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

SOURCE: CYTOMETRY, (1996 Sep 1) 25 (1) 14-20.  
Journal code: D92; 8102328. ISSN: 0196-4763.

PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199702

ENTRY DATE: Entered STN: 19970305  
Last Updated on STN: 19990129  
Entered Medline: 19970218

AB Multidrug resistance (MDR) is often related to expression of P-glycoprotein (Pgp) or Multidrug Resistance Protein (MRP). Pgp-mediated MDR can be evaluated by determining cellular retention of fluorescent substrates by flow cytometry. This study determined if agents used to evaluate Pgp function also can be used to evaluate MRP function. Cellular retention of doxorubicin (Dox), Rhodamine-123 (Rh-123), and 3,3'-diethyloxacarbocyanine iodide (DiOC2(3)) were studied in MRP-expressing cell lines (HL60/Adr and HT1080/DR4), whereas a Pgp expressing cell line (A2780/Dx5) served as a positive control. Overexpression of Pgp correlated inversely with retention of Dox, Rh-123, and DiOC2(3); however, under identical experimental conditions (1 h reincubation in drug-free medium), no retention difference of the three agents was detected between parental and MRP-expressing resistant cells. Upon extending the reincubation time to 4 h, an efflux of Rh-123 and Dox in the resistant lines became apparent and even more pronounced after 24h; however, still no efflux was detectable for DiOC2(3). Incubation of the cells with a **modulator** of MDR, PAK-104P, negated the observed drug efflux in Pgp and MRP expressing cells, which correlated with increased sensitivity of the MDR lines to doxorubicin. Thus both Dox and Rh-123 can be used to evaluate MRP-function, but DiOC2(3) can not.

L7 ANSWER 104 OF 141 MEDLINE DUPLICATE 61



L7 ANSWER 99 OF 141 MEDLINE DUPLICATE 57

ACCESSION NUMBER: 96184396 MEDLINE  
DOCUMENT NUMBER: 96184396 PubMed ID: 8612802  
TITLE: Transport properties of the **multidrug resistance**-associated protein (MRP) in human tumour cells.  
AUTHOR: Hollo Z; Homolya L; Hegedus T; Sarkadi B  
CORPORATE SOURCE: National Institute of Haematology and Immunology, Budapest, Hungary.  
SOURCE: FEBS LETTERS, (1996 Mar 25) 383 (1-2) 99-104.  
JOURNAL code: EUH; 0155157. ISSN: 0014-5793.  
PUB. COUNTRY: Netherlands  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199606  
ENTRY DATE: Entered STN: 19960613  
Last Updated on STN: 19970203  
Entered Medline: 19960606

AB In this paper we demonstrate that the expression of the multidrug resistance-associated protein (MRP) in a variety of intact human tumour cells results in the ATP-dependent, mutually exclusive extrusion of both the acetoxymethyl ester and the free anion forms of the fluorescent dye calcein, as well as that of a fluorescent pyrenemaleimide-glutathione conjugate. The MRP-dependent transport of all these three model compounds closely correlates with the expression level of MRP and is

cross-inhibited

by hydrophobic anticancer drugs, by **reversing** agents for MDR1, and also by compounds not influencing MDR1, such as hydrophobic anions, alkylating agents, and inhibitors of organic anion transporters. Cellular glutathione depletion affects neither the MRP-dependent extrusion of calcein AM or free calcein, nor its **modulation** by most hydrophobic or anionic compounds, although eliminating the cross-inhibitory effect of glutathione conjugates. These results suggest that the outward pumping of both hydrophobic uncharged and water-soluble anionic compounds, including glutathione conjugates, is an inherent property of MRP, and offer sensitive methods for the functional diagnostics of this transport protein as well as for the rapid screening of drug-resistance **modulating** agents.

L7 ANSWER 98 OF 141 MEDLINE DUPLICATE 56

ACCESSION NUMBER: 96326622 MEDLINE

DOCUMENT NUMBER: 96326622 PubMed ID: 8706899

TITLE: Transport of the glutathione conjugate of ethacrynic acid  
by the human **multidrug resistance**  
protein **MRP**.

AUTHOR: Zaman G J; Cnubben N H; van Bladeren P J; Evers R; Borst P

CORPORATE SOURCE: Division of Molecular Biology, Netherlands Cancer  
Institute, Amsterdam, The Netherlands.

SOURCE: FEBS LETTERS, (1996 Aug 5) 391 (1-2) 126-30.  
Journal code: EUH; 0155157. ISSN: 0014-5793.

PUB. COUNTRY: Netherlands  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199609

ENTRY DATE: Entered STN: 19960919  
Last Updated on STN: 19970203  
Entered Medline: 19960912

AB The multidrug resistance protein MRP has been shown to mediate the  
transport of glutathione S-conjugates across membranes. In this study we  
demonstrate that the glutathione S-conjugate of the diuretic drug  
ethacrynic acid, which is an efficient inhibitor of glutathione  
S-transferases, is a high-affinity substrate and inhibitor of the  
glutathione S-conjugate pump associated with MRP. This implies that  
ethacrynic acid may **modulate** drug resistance of tumor cells not  
only by inhibiting glutathione S-transferase activity, but also by  
inhibiting the export of drug conjugates from the cell by MRP.

L7 ANSWER 99 OF 141 MEDLINE DUPLICA

L7 ANSWER 93 OF 141 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER:- 1996:256385 BIOSIS

DOCUMENT NUMBER: PREV199698812514

TITLE: VX-853: A novel bispecific chemosensitizer which  
**reverses** P-glycoprotein- and **MRP**-mediated  
**multidrug resistance**.

AUTHOR(S): Germann, U. A.; Shlyakhter, D.; Mason, V. S.; Ford, P. J.;  
Harding, M. W.

CORPORATE SOURCE: Vertex Pharmaceuticals Inc., Cambridge, MA 02139 USA

SOURCE: Proceedings of the American Association for Cancer

Research

Annual Meeting, (1996) Vol. 37, No. 0, pp. 335.

Meeting Info.: 87th Annual Meeting of the American

Association for Cancer Research Washington, D.C., USA

April

20-24, 1996

ISSN: 0197-016X.

DOCUMENT TYPE: Conference

LANGUAGE: English

L7 ANSWER 84 OF 141 MEDLINE DUPLICATE 49  
ACCESSION NUMBER: 96296553 MEDLINE  
DOCUMENT NUMBER: 96296553 PubMed ID: 8763341  
TITLE: Experimental **modulation** of **MRP** (  
**multidrug resistance**-associated  
protein)-mediated resistance.  
AUTHOR: Twentyman P R; Versantvoort C H  
CORPORATE SOURCE: MRC Clinical Oncology and Radiotherapeutics Unit, Medical  
Research Council Centre, Cambridge, U.K.  
SOURCE: EUROPEAN JOURNAL OF CANCER, (1996 Jun) 32A (6)  
1002-9. Ref: 61  
Journal code: ARV; 9005373. ISSN: 0959-8049.  
PUB. COUNTRY: ENGLAND: United Kingdom  
Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, ACADEMIC)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199610  
ENTRY DATE: Entered STN: 19961022  
Last Updated on STN: 19961022  
Entered Medline: 19961009

L7 ANSWER 79 OF 141 CANCERLIT

ACCESSION NUMBER: 96709614 CANCERLIT

DOCUMENT NUMBER: 96709614

TITLE: Reduced expression of the **multidrug resistance** protein, **MRP**, in human tumor cells by antisense oligonucleotides (Meeting abstract).

AUTHOR: Neverova I; Stewart A J; Canitrot Y; Baracchini E; Dean N M; Deeley R G; Cole S P

CORPORATE SOURCE: Cancer Res. Laboratories, Kingston, Ontario, K7L 3N6.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1996). Vol.

37, pp. A2113.

ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199610

AB Multidrug Resistance Protein (MRP) is overexpressed in many multidrug resistant cell lines and has been shown to cause multidrug resistance when

transfected into previously sensitive cells. We have found that MRP mRNA and protein levels are reduced in transfected HeLa cells after treatment with MRP antisense oligonucleotides. Sixteen eicosomeric phosphorothioate oligonucleotides complementary to different regions along the entire length of the MRP mRNA were able to inhibit expression of MRP to some degree. One oligonucleotide, ISIS 7597 and two 'winged' 2' O-propyl derivatives ISIS 11471 and ISIS 9659, targeted to the coding region of the

MRP mRNA, **decreased** MRP mRNA levels to less than 10% of control levels in a dose-dependent manner. This effect was transient and MRP mRNA levels returned to control levels less than 96 h after treatment. A

double treatment with ISIS 7597 produced a sustained inhibition, resulting in a greater than 90% reduction in MRP mRNA for 72 h and a comparable **decrease** in protein levels. Increased sensitivity to doxorubicin was observed under these conditions. Northern blotting analyses using two DNA probes corresponding to sequence 5' and 3' of ISIS 7597 target sequence, respectively, revealed the presence of low levels of two

smaller sized RNA fragments. These studies provide strong evidence for RNase H mediated destruction of a specific mRNA in intact cells following treatment with phosphorothioate oligonucleotides. They further suggest that antisense oligonucleotides may prove to be a feasible approach to circumvent resistance mediated by MRP.

L7 ANSWER 80 OF 141

MEDLINE

DUPLICATE 46

L7 ANSWER 76 OF 141 CANCERLIT

ACCESSION NUMBER: 97608474 CANCERLIT

DOCUMENT NUMBER: 97608474

TITLE: VX-853: a novel bispecific chemosensitizer which  
**reverses** P-glycoprotein- and **MRP**-mediated  
**multidrug resistance** (Meeting abstract).

AUTHOR: Germann U A; Shlyakhter D; Mason V S; Ford P J; Harding M  
W

CORPORATE SOURCE: Vertex Pharmaceuticals Incorporated, Cambridge, MA 02139.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1996). Vol.  
37, pp. A2283.  
ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199704

AB Both the human multidrug resistance MDR1 gene product P-glycoprotein and  
the multidrug resistance-associated protein MRP have been associated with  
drug resistance in tumor cells and may represent major obstacles to  
successful cancer chemotherapy. VX-853 is a specifically designed MDR  
**reversing** agent that restores drug sensitivity in a variety of  
MDR1- or MRP-expressing multidrug resistant cells, including 8226/Dox6  
myeloma cells, HL60/Vinc and HL60/ADR promyelocytic leukemia cells, MDR1  
cDNA-transfected L1210vMDRC.06 leukemia cells and N3V2400 fibroblasts,

and

MRP cDNA-transfected 36-8-32 NIH 3T3 fibroblasts. In 3-day cytotoxicity

or

14-day colony formation assays, VX-853 restores daunorubicin accumulation  
(IC50 0.2-0.4 uM) and blocks daunorubicin and rhodamine-123 efflux (IC50  
0.3-0.6 uM) demonstrating the functional action of VX-853 on  
P-glycoprotein or MRP-mediated drug transport. Competitive displacement

of

P-glycoprotein-specific photoaffinity ligands by VX-853 and stimulation

of

P-glycoprotein ATPase activity by VX-853 (ka approx 50 nM) indicate a  
direct interaction of VX-853 with the MDR1 gene product. Inhibition of  
both MDR1- and MRP-mediated drug efflux by VX-853 suggests a greater  
potential for clinical benefit in treating patients with MDR cancers.

L7 ANSWER 75 OF 141 CANCERLIT

ACCESSION NUMBER: 96649891 CANCERLIT

DOCUMENT NUMBER: 96649891

TITLE: Differential activity of topoisomerase I inhibitors in  
**multidrug resistance** protein (MRP  
) and P170-glycoprotein (Pgp) mediated **multidrug  
resistance** (MDR) (Meeting abstract).

AUTHOR: Voigt W; Vanhoefer U; Yin M B; Hausheer F; Rustum Y M

CORPORATE SOURCE: Roswell Park Cancer Inst., Buffalo, NY 14263.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1996). Vol.  
37, pp. A3013.  
ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199608

AB The in vitro activity of topoisomerase I (Topo I) inhibitors camptothecin (CPT), SN-38, SN-22 and BNP1099 was evaluated in human ovarian carcinoma cell lines A2780 WT (parental) and 40-fold doxorubicin (Dox) resistant A2780 DX5 (Pgp+, MRP-) and fibrosarcoma cell lines HT1080 (parental) and 250 fold Dox resistant HT1080/DR4 (MRP+, Pgp-). Overexpression of Pgp and MRP was confirmed using Northern and Western blot analysis. The four Topo I inhibitors demonstrated no cross resistance in the MRP-mediated MDR cells. The A2780 DX5 cells were not cross resistant to SN-22 and BNP1099 and a 3-4 fold cross resistance against SN-38 and CPT could be completely **reversed** by the MDR-inhibitor PAK-200S. Topo I inhibiting activity was determined by drug inhibition assay where BNP1099 and SN-22 exerted the highest activity. A correlation between Topo I protein (Immunoblot) and specific activity of Topo I (DNA unwinding assay) was demonstrated

for

all cell lines. Topo I protein expression was lower in the A2780 DX5 as compared to the parental cell line but no significant difference was detected between HT1080 and HT1080/DR4 cells. Conclusions: (1) no cross resistance was seen with the Topo I inhibitors BNP1099 and SN-22 in MRP- and Pgp-mediated MDR, (2) CPT and SN-38 however exhibited low degree of cross resistance in Pgp-mediated MDR which could be completely **reversed** by PAK-200S, (3) Topo I protein expression and specific activity do not appear to correlate with the observed differences in drug activity.

L7 ANSWER 74 OF 141 CANCERLIT

ACCESSION NUMBER: 96649897 CANCERLIT

DOCUMENT NUMBER: 96649897

TITLE: CPT-11 sensitivity in relation to P170-glycoprotein (Pgp) and **multidrug-resistance** associated protein (MRP) expression investigated in vitro and in human tumor xenografts (Meeting abstract).

AUTHOR: Jansen W J; Hulscher T M; Giaccone G; Pinedo H M; Boven E

CORPORATE SOURCE: Dept. of Medical Oncology, Academic Hosp. Vrije Universiteit, Amsterdam, The Netherlands.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1996). Vol. 37, pp. A3019.

ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199608

AB CPT-11 has been reported to have a low level of cross-resistance in Pgp-positive cell lines in vitro, but not in Pgp-positive tumors in vivo. We studied the relevance of Pgp as well as MRP for the sensitivity to CPT-11 in the Pgp-positive BRO/mdr1.1 and 2780AD cell lines and the MRP-positive SW1573/S1 (MRP) and GLC4/ADR cell lines. The antiproliferative effects of CPT-11 +/- carboxylesterase (CE, 1 ug/ml) were measured by means of the MTT assay. The Pgp-positive cells showed a 25-fold resistance to CPT-11 + CE when compared to the sensitive cells. Addition of Pgp-**modulators** at non-toxic concentrations could **reverse** this resistance. From the results in the SW1573/S1 (MRP) and GLC4/ADR cells it appeared that CPT-11 +/- CE was not a substrate of MRP. Parent and Pgp-positive cells were grown as bilateral sc xenografts in nude mice. CPT-11 20 mg/kg ip daily x 5 was started when tumors measured approx 150 mm<sup>3</sup>. Efficacy was expressed as % growth inhibition (100%-treated/control%). BRO/mdr1.1 tumors were similarly sensitive to CPT-11 than BRO tumors. However, 2780AD tumors were less sensitive than A2780 tumors. This could be attributed to a 2.5-fold lower topoisomerase

I activity in 2780AD cells. In conclusion, (1) Pgp expression is related to a low degree of cross-resistance to CPT-11 in vitro, but not in vivo; (2) MRP expression does not appear to affect the sensitivity to CPT-11.

L7 ANSWER 75 OF 141 CANCERLIT



L7 ANSWER 72 OF 141 MEDLINE

DUPLICATE 45

ACCESSION NUMBER: 97332562 MEDLINE

DOCUMENT NUMBER: 97332562 PubMed ID: 9188796

TITLE: Anthracyclines **modulate multidrug resistance** protein (MRP) mediated organic anion transport.

AUTHOR: Heijn M; Hooijberg J H; Scheffer G L; Szabo G; Westerhoff H

V; Lankelma J

CORPORATE SOURCE: Academic Hospital Vrije Universiteit, Department of Medical

Oncology, Amsterdam, The Netherlands.

SOURCE: BIOCHIMICA ET BIOPHYSICA ACTA, (1997 May 22) 1326 (1) 12-22.

Journal code: AOW; 0217513. ISSN: 0006-3002.

PUB. COUNTRY: Netherlands

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199707

ENTRY DATE: Entered STN: 19970716

Last Updated on STN: 19970716

Entered Medline: 19970702

AB We studied the ATP-dependent uptake of dinitrophenyl-glutathione (GS-DNP) into plasma membrane vesicles derived from parental GLC4 cells and from multidrug resistant GLC4/ADR cells. The latter have a high expression of the multidrug resistance protein (MRP). Uptake of GS-DNP into membrane vesicles from GLC4/ADR cells was highly stimulated by the addition of

ATP, compared to the uptake into membrane vesicles from GLC4 cells. This ATP-dependent uptake into membrane vesicles from GLC4/ADR cells was saturable with a Km of 1.2 +/- 0.2 microM and a Vmax of 560 +/- 80 pmol/mg

prot./min. ATP stimulated GS-DNP uptake with a Km of 187 +/- 4 microM. This uptake was specifically inhibited by a polyclonal serum raised against a fusion protein containing a segment of MRP. The ATP-dependent uptake of GS-DNP was not only inhibited by organic anions, such as oxidized glutathione (GSSG), methotrexate (MTX) and some bile acids, but also by non-anionic natural product drugs, such as anthracyclines, vinca alkaloids and etoposide (VP-16). Uptake of GSSG and MTX into membrane vesicles from GLC4/ADR cells could be stimulated by ATP. The

ATP-dependent uptake of GSSG had a Km of 43 +/- 3 microM and a Vmax of 900 +/- 200 nmol/mg protein/min. The ATP-dependent uptake of GS-DNP seemed to be non-competitively inhibited by the anthracycline daunorubicin (DNR), whereas the ATP-dependent GSSG uptake seemed to be competitively inhibited

by DNR. A substrate binding site on MRP is proposed that comprises a pocket in which both DNR and GS-DNP or GSSG bind in random order to different, only partly overlapping sites. In this pocket binding of a second compound is influenced by the compound which was bound first.

L7 ANSWER 73 OF 141 BIOTECHDS COPYRIGHT 2002 THOMSON DERWENT AND ISI

L7 ANSWER 70 OF 141 MEDLINE

DUPLICATE 43

ACCESSION NUMBER: 1998070912 MEDLINE

DOCUMENT NUMBER: 98070912 PubMed ID: 9405241

TITLE: The quinoline-based drug, N-[4-[1-hydroxy-2-(dibutylamino)ethyl] quinolin-8-yl]-4-azidosalicylamide, photoaffinity labels the **multidrug resistance** protein (MRP) at a biologically relevant site.

AUTHOR: Vezmar M; Deady L W; Tilley L; Georges E

CORPORATE SOURCE: Institute of Parasitology, McGill University, Macdonald Campus, Ste-Anne de Bellevue, Quebec, Canada.

SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1997 Dec 8) 241 (1) 104-11.

Journal code: 9Y8; 0372516. ISSN: 0006-291X.

PUB. COUNTRY: United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199801

ENTRY DATE: Entered STN: 19980129

Last Updated on STN: 19980129

Entered Medline: 19980115

AB MRP is a member of the ABC trafficking proteins thought to mediate the transport of glutathione S-conjugates and amphiphilic natural products. However, unlike P-glycoprotein, the biochemical mechanism by which MRP mediates the resistance to cytotoxic drugs is not clear. In this report, we describe the interactions of a quinoline-based drug, N-4-[1-hydroxy-2-(dibutylamino)ethyl] quinolin-8-yl -4-azidosalicylamide (IAAQ), with MRP. Our results demonstrate the ability of IAAQ to photoaffinity label a 190 kDa protein in resistant Small Cell Lung Cancer cells (H69/AR) but not in the parental H69 cells. The photoaffinity labeling of the 190 kDa protein with IAAQ was both saturable and specific.

The identity of the 190 kDa protein, as MRP, was confirmed by immunoprecipitation with the monoclonal antibody, QCRL-1. Furthermore, a molar excess of LTC4, MK 571 or vinblastine inhibited the photoaffinity labeling of MRP with IAAQ in intact cells and plasma membranes. Cell growth and drug transport studies showed H69/AR cells to be less sensitive

to and to accumulate less IAAQ than the parental H69 cells. In addition, MK 571 and doxorubicin increased the sensitivity to and the accumulation of IAAQ in H69/AR cells. Together, the results of this study show for the first time the direct binding of unaltered cytotoxic drug to MRP. Moreover, given the structural similarities between IAAQ and MK 571, we suggest that MK 571 **modulates** MRP-mediated resistance by direct binding to MRP.

Copyright 1997 Academic Press.

L7 ANSWER 67 OF 141 MEDLINE DUPLICATE 40  
ACCESSION NUMBER: 97226040 MEDLINE  
DOCUMENT NUMBER: 97226040 PubMed ID: 9073310  
TITLE: Chemosensitization and drug accumulation effects of  
VX-710,

verapamil, cyclosporin A, MS-209 and GF120918 in  
**multidrug resistant** HL60/ADR cells  
expressing the **multidrug resistance**  
-associated protein **MRP**.

AUTHOR: Germann U A; Ford P J; Shlyakhter D; Mason V S; Harding M  
W

CORPORATE SOURCE: Vertex Pharmaceuticals Inc., Cambridge, MA 02139-4242,  
USA.

SOURCE: ANTI-CANCER DRUGS, (1997 Feb) 8 (2) 141-55.  
Journal code: A9F; 9100823. ISSN: 0959-4973.

PUB. COUNTRY: ENGLAND: United Kingdom  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199706

ENTRY DATE: Entered STN: 19970630

Last Updated on STN: 19970630

Entered Medline: 19970616

AB Overexpression of the multidrug resistance MDR1 gene product  
P-glycoprotein and/or the multidrug resistance-associated protein MRP  
confers multidrug resistance to cancer cells. The pipercolinate derivative  
VX-710 has previously been demonstrated to **reverse** MDR1-mediated  
multidrug resistance at concentrations of 0.5-2.5 microM by direct  
interaction with P-glycoprotein and inhibition of its drug efflux  
activity. In this study we investigated whether VX-710 as well as four  
other known MDR1 **modulators** could also **reverse**  
multidrug resistance mediated by MRP. VX-710 at 0.5-5 microM restored  
sensitivity of MRP-expressing HL60/ADR promyelocytic leukemia cells to the  
cytotoxic action of doxorubicin, etoposide and vincristine. VX-710 was  
approximately 2-fold more effective than verapamil, MS-209 and CsA in  
**modulating** MRP-mediated multidrug resistance, whereas GF120918 had  
no significant effect. VX-710 was also more effective than verapamil,  
MS-209 and CsA in restoring the daunorubicin accumulation deficit in  
HL60/ADR cells and in increasing calcein uptake. A photoaffinity analog

of

VX-710, [3H]VF-13,159, specifically photo labeled the MRP protein and  
unlabeled VX-710 inhibited this binding in a concentration-dependent  
manner. These data suggest that VX-710 is not only a potent  
**modulator** of P-glycoprotein-mediated multidrug resistance, but  
also affects multidrug resistance in MRP-expressing cells and may exert  
its action, at least in part, by binding directly to MRP.

L7 ANSWER 62 OF 141 MEDLINE DUPLICATE 36

ACCESSION NUMBER: 97418083 MEDLINE

DOCUMENT NUMBER: 97418083 PubMed ID: 9272120

TITLE: A novel quinoline derivative, MS-209, overcomes **drug resistance** of human lung cancer cells expressing the **multidrug resistance**-associated protein (MRP) gene.

AUTHOR: Narasaki F; Oka M; Fukuda M; Nakano R; Ikeda K; Takatani H;  
Terashi K; Soda H; Yano O; Nakamura T; Doyle L A; Tsuruo T;  
Kohno S

CORPORATE SOURCE: Second Department of Internal Medicine, Nagasaki University  
School of Medicine, Japan.

SOURCE: CANCER CHEMOTHERAPY AND PHARMACOLOGY, (1997) 40 (5) 425-32.  
Journal code: C9S; 7806519. ISSN: 0344-5704.

PUB. COUNTRY: GERMANY: Germany, Federal Republic of  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199709

ENTRY DATE: Entered STN: 19970922  
Last Updated on STN: 19970922  
Entered Medline: 19970910

AB PURPOSE AND METHODS: MS-209 is a newly synthesized quinoline compound used orally to overcome human P-glycoprotein (Pgp)-mediated multidrug resistance (MDR). The multidrug resistance-associated protein (MRP) gene is thought to play an important role in MDR in lung cancer. To investigate whether MS-209 could also overcome MRP-mediated MDR, we examined the effect of the compound using a cytotoxicity assay on MDR1 gene-negative drug-selected MDR and wildtype lung cancer cells with various levels of MRP gene expression. The effects of MS-209 were compared with those of verapamil (VER) and cyclosporin A (CsA). The level of MRP gene expression in the cells was evaluated semiquantitatively by RT-PCR. For vincristine (VCR), intracellular accumulation of [3H]-VCR was measured with or without MS-209. RESULTS: In MDR UMCC-1/VP small-cell lung carcinoma cell line, 5 microM of MS-209 and VER enhanced the cytotoxicity of etoposide, doxorubicin (DOX) and VCR more than twofold, and completely **reversed** the resistance to VCR. The mean **reversing** effects of MS-209 on DOX and VCR were significantly stronger than those of VER and CsA. In wildtype non-small-cell lung carcinoma cells, the effects of MS-209 were almost equal to those of VER and CsA. The effect of these three agents correlated with the level of MRP gene expression. The MS-209-induced increase in intracellular accumulation of VCR was proportional to the level of MRP gene expression in these cells. CONCLUSION: Our results indicate that MS-209 is a potentially useful drug that can overcome MRP-mediated intrinsic and acquired MDR in human lung cancer.

L7 ANSWER 63 OF 141 CANCERLIT

L7 ANSWER 39 OF 141 CANCERLIT

ACCESSION NUMBER: 1998640215 CANCERLIT

DOCUMENT NUMBER: 98640215

TITLE: Diverse effects of tumor necrosis factor alpha on expression of the **multidrug resistance** -associated genes LRP and **MRP** (Meeting abstract).

AUTHOR: Stein U; Walther W; Laurencot C M; Scheffer G L; Scheper R J; Shoemaker R H

CORPORATE SOURCE: Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany 13122.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A3215.  
ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199803

AB It has previously been shown that treatment of multidrug resistant human tumor cells with cytokines can result in their sensitization towards drugs. Recently, we have reported that in vitro treatment of colon carcinoma cells with human tumor necrosis factor alpha (TNF) or transduction of the human TNF gene is associated with reduced expression of the mdrl gene at the mRNA, protein and functional level. To investigate

this phenomenon in relation to the more recently described MDR-associated genes LRP (lung resistance protein) and MRP (multidrug resistance associated protein), we evaluated the effect of TNF on the mRNA level by RT-PCR and on the protein level by immuno flow cytometry. Human colon carcinoma cell lines HCT15 and HCT116 were incubated with TNF for 2, 12, 24, 48 or 72 hours, or were transduced with the human TNF gene.

**Modulated** expression of LRP and MRP was observed under both treatment conditions: LRP expression was reduced by TNF in an apparently time- and dose-related fashion. In contrast, MRP expression was increased on both expression levels. These results illustrate the complexity of multiple MDR phenotypes, which may coexist within a tumor cell population.

They further suggest that strategies for **reversal** of MDR should not focus exclusively on the mdrl gene, but should also address the net effect of MDR mechanisms which may respond in coordinate, or contrasting ways to **modulating** agents.

L7 ANSWER 38 OF 141 CANCERLIT

ACCESSION NUMBER: 1998640968 CANCERLIT

DOCUMENT NUMBER: 98640968

TITLE: The steroidal agent ZK112993 inhibits the **multidrug resistance** (MDR) phenotype associated with the expression of the **multidrug resistance** protein (**MRP**) (Meeting abstract).

AUTHOR: Leonessa F; Green G; Lippman J; Clarke R

CORPORATE SOURCE: Vincent T Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A3968.  
ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199802

AB 17beta-estradiol-17(beta-D-glucuronide) (E2G) is implicated as a substrate

for MRP. Thus, steroids, by a competitive mechanism, may interfere with the MDR phenotype conferred by MRP. We tested the chemosensitizing activity of several steroids on MCF7/VP, a cell line derived by selection of MCF-7 human breast cancer cells with etoposide. MCF7/VP cells exhibit an MDR phenotype, and express MRP, but not P-glycoprotein. Estrone, estrone-3-sulfate, 17beta-estradiol, E2G, progesterone, hydrocortisone, cholesterol and 5-choleric acid-3beta-ol, at achievable non-toxic concentrations, did not show any significant chemosensitizing activity with respect to doxorubicin (Dx). However, we observed a 1.7 fold sensitization by ZK112993, a steroidal antiprogestational agent carrying

a

bulky moiety including an aromatic ring at the C11 position. Further evaluations confirmed that ZK112993 increases the cytotoxic effect of Dx in MCF7/VP and, to a much lesser extent, in MCF-7 cells. Even after correction for the a specific effect, results show that ZK112993 causes a dose-dependent sensitization in MCF7/VP cells, which reaches more than 2-fold at 5 uM. Isobologram analysis confirmed that interaction is synergistic, as would be predicted for a MRP-**reversing** agent, and that the increased inhibition is not the result of additive toxicity.

L7 ANSWER 36 OF 141 CANCERLIT

ACCESSION NUMBER: 1998640974 CANCERLIT

DOCUMENT NUMBER: 98640974

TITLE: Synergistic effects of doxorubicin and **modulators** of **multidrug resistance** in small cell lung cancer (SCLC) cells naturally expressing MDR-1, **MRP** and LRP phenotypes (Meeting abstract).

AUTHOR: Chan D; Helfrich B; Helm K; Chou T; Bunn P

CORPORATE SOURCE: Univ. of Colorado Cancer Center, Denver, CO 80262.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A3974.  
ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199802

AB In this report we have evaluated six different MDR **modulators** including Verapamil (Vpm), Dexverapamil (Dvpm), Cyclosporin A (CSA), PSC 833 (P833), Niguldipine (Ngd) and Dexniguldipine (Dngd) in a SCLC cell line SHP 77 which has a classical MDR phenotype. It has a reduced Rhodamine R123 uptake and a reduced sensitivity to doxorubicin when compared to other SCLC cell lines that do not have MDR. This cell line was established from a patient before chemotherapy. It has not been exposed to drug selection and has elevated expression of MDR (50%+), LRP (49%+) and MRP (29%) phenotype, as demonstrated with three different monoclonal antibodies (Mab 4E3, MRPM6 and LRP-56). Cells were treated with doxorubicin from 0.001 to 2 ug/ml in the absence or presence of the **modulator** ranging from 0.001 to 20 uM. MTT growth assay was used to measure the cytotoxicity of the agents. The data were then analyzed by a CalcuSyn software using the combination index-isobologram method, which is based on the median-effect principle (TIP Sci 4:450 1983). Mutually exclusive (conventional) isobologram was used to calculate the combination-indexes (CI), where CI more than 1, CI=1 CI less than 1 indicates **antagonism**, additive effect and synergism. Strong synergisms were found for all of these agents with potencies ranking as CSA more than Vpm more than Dngd more than Dvpm more than P833 more than Ngd. However, because of the unfavorable side-effects from CSA (immunosuppressive), Vpm and Ngd (cardiovascular toxicities), we conclude that the other three agents Dngd more than Dvpm more than P833 may provide a better clinically achievable **modulatory** effects for chemosensitizer treatment of cancer patients.

L7 ANSWER 35 OF 141 CANCERLIT

ACCESSION NUMBER: 1998640989 CANCERLIT

DOCUMENT NUMBER: 98640989

TITLE: **Reversal of MRP-associated drug resistance** by the pyridine analog, PAK-104P (Meeting abstract).

AUTHOR: Chuman Y; Chen Z S; Sumizawa T; Seto K; Furukawa T; Haraguchi M; Tani A; Shudo N; Yamada K; Akiyama S; Aikou T  
CORPORATE SOURCE: Kagoshima University, Sakuragaoka 8-35-1, Kagoshima 890, Japan.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A3989.  
ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199802

AB Three agents, verapamil, cepharanthine and 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl 5-(trans-4,6-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-2,6-di methyl-4-(3-nitrophenyl)-3-pyridinecarboxylate P-oxide (PAK-104P), that

**reverse** drug resistance in P-glycoprotein (P-gp)-mediated multidrug resistant cells were examined for their activity to **reverse** drug resistance in multidrug resistance (MDR)-associated protein (MRP)-mediated multidrug resistant C-A120 cells. The agents other than PAK-104P could not **reverse** the resistance to doxorubicin (ADM) in C-A120 cells. PAK-104P moderately **reversed** the ADM resistance. In contrast, PAK-104P almost completely **reversed** the resistance to vincristine (VCR) in C-A120 cells as well as KB-8-5 cells and other agents moderately **reversed** the VCR resistance in C-A120 cells. PAK-104P at 10 uM enhanced the accumulation of VCR in C-A120

cells to the level of that in KB-3-1 cells without the agent. PAK-104P competitively inhibited the ATP-dependent [3H]leukotriene C4 uptake in membrane vesicles isolated from C-A120 cells. These findings demonstrate that PAK-104P can completely **reverse** the resistance to VCR in both P-gp- and MRP-mediated MDR cells, and that PAK-104P directly interacts with MRP and inhibits the transporting activity of MRP.



L7 ANSWER 30 OF 141 MEDLINE

DUPLICATE 24

ACCESSION NUMBER: 1998366080 MEDLINE

DOCUMENT NUMBER: 98366080 PubMed ID: 9700723

TITLE: Development of novel **reversal** agents,  
imidazothiazole derivatives, targeting MDR1- and  
**MRP-mediated multidrug resistance**

AUTHOR: Naito S; Koike K; Ono M; Machida T; Tasaka S; Kiue A; Koga  
H; Kumazawa J

CORPORATE SOURCE: Department of Urology, Faculty of Medicine, Kyushu  
University, Fukuoka, Japan.. naito@uro.med.kyushu-u.ac.jp

SOURCE: ONCOLOGY RESEARCH, (1998) 10 (3) 123-32.  
Journal code: BBN; 9208097. ISSN: 0965-0407.

PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199810

ENTRY DATE: Entered STN: 19990106  
Last Updated on STN: 19990106  
Entered Medline: 19981029

AB Three newly synthesized imidazothiazole derivatives (N276-12, N276-14,  
N276-17) were examined regarding their ability and mechanism as a  
chemosensitizing agent against multidrug resistance 1 (MDR1)-mediated and  
multidrug resistance-associated protein (MRP)-mediated MDR. All three

N276 compounds almost completely **reversed** the acquired resistance to  
vincristine (VCR), vinblastine (VBL), and doxorubicin (DXR) in  
MDR1-overexpressing human cancer cell lines (KB/VJ300 and T24/VCR). Their  
**reversal** effect against acquired resistance to VCR, DXR, and  
etoposide (VP16) was partial but clearly observed in the cell line  
expressing MRP (KB/VP4). All three N276 compounds enhanced the  
intracellular accumulation of [3H]VCR in MDR1-overexpressing KB/VJ300  
cells through the inhibition of the increased efflux of the drug. They  
(100 microM) almost completely inhibited the photoaffinity labeling of  
P-glycoprotein encoded by the MDR1 gene. All the N276 compounds also  
remarkably enhanced the sensitivity to VBL and DXR in both MDR1- and  
MRP-overexpressing renal cell carcinoma (RCC) cell line (NKK1), whereas  
they showed no potentiation of these anticancer agents in an RCC cell

line (KPK1) expressing neither MDR1 nor MRP. The combination chemotherapy of  
VCR or VP16 with N276-12 significantly increased the life span of mice  
inoculated i.p. or i.v. with drug-resistant P388/VCR cells without any  
significant side effects, whereas chemotherapy with the anticancer agent  
alone did not increase the life span at all. These results suggest that  
these newly synthesized imidazothiazole derivatives can be a useful  
chemosensitizing agent against not only MDR1- but also MRP-mediated MDR.

L7 ANSWER 22 OF 141 MEDLINE DUPLICATE 16

ACCESSION NUMBER: 1998379134 MEDLINE

DOCUMENT NUMBER: 98379134 PubMed ID: 9713512

TITLE: Co-transfection of MDR1 and **MRP** antisense RNAs abolishes the **drug resistance** in **multidrug-resistant** human lung cancer cells.

AUTHOR: Gao Z; Gao Z; Fields J Z; Boman B M

CORPORATE SOURCE: Cancer Research Laboratory, CA\*TX, Inc., Omaha, NE 68103, USA.

CONTRACT NUMBER: R21 CA71531-02 (NCI)

SOURCE: ANTICANCER RESEARCH, (1998 Jul-Aug) 18 (4C) 3073-6.  
Journal code: 59L; 8102988. ISSN: 0250-7005.

PUB. COUNTRY: Greece  
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199809

ENTRY DATE: Entered STN: 19980917  
Last Updated on STN: 19980917  
Entered Medline: 19980910

AB The resistance of lung cancer cells to the therapeutic actions of anticancer drugs is a serious clinical problem often encountered during cancer chemotherapy. It is very important, therefore, to investigate how to prevent and/or **reverse** this drug resistance. To this end, we took advantage of the fact that the overexpression of MDR1 and MRP genes, two genes known to be associated with the development of drug resistance, is very common in lung cancer. We used antisense RNA in an attempt to prevent expression of the protein products of these genes. Using a retrovirus, we introduced the antisense RNAs of MDR1 and MRP genes into doxorubicin-selected, multidrug-resistant GAOK cells, a cell which overexpresses both MDR1 and MRP genes. The expression levels of the products of the MDR1 gene (Pgp) and MRP gene (Mrp) in the transfected cells were analyzed using flow cytometry, and the drug resistances of the transfected cells were detected by a cell viability (MTT) assay. The expression of Pgp and Mrp in the transfected cells was almost completely inhibited by the antisense RNAs: expression levels **decreased** 64% and 93%, respectively. In parallel, the drug resistance of these cells **decreased** about 99% to doxorubicin, 98% to vinblastine, and 97% to colchicine. These results show that: a) antisense RNAs can attenuate drug resistance, an inhibition that might lead to new treatments for patients who are, or become, refractory to conventional chemotherapy; b) MDR1 and MRP appear to be cooperating to confer drug resistance in GAOK cells.

L7 ANSWER 23 OF 141 MEDLINE DUPLICATE 17

L7 ANSWER 21 OF 141 CANCERLIT

ACCESSION NUMBER: 1998700915 CANCERLIT

DOCUMENT NUMBER: 98700915

TITLE: PROBENECID AS A POTENTIAL **MODULATOR** OF

**DRUG RESISTANCE** IN THE **MRP**

OVEREXPRESSING BREAST CANCER CELL LINE MCF7-VP (Meeting abstract).

AUTHOR: Dearden T; Chadderton A; Yan B; Bewick M; Rhude A; Parissenti A; Gluck S

CORPORATE SOURCE: The Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada.

SOURCE: Proc Annu Meet Am Soc Clin Oncol, (1998). Vol. 17, pp. A917.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199910

AB Numerous mechanisms of drug resistance in breast cancer have been described in the past. While the significance of these mechanisms in the clinical setting are unclear, means of **modulating** drug resistance in vitro are being explored. The Multidrug Resistance Associated Protein (MRP) has been shown to be capable of transporting a range of chemotherapeutic agents and has become a potential target of **reversing** agents. The breast cancer cell line MCF7-VP was selected by exposure to VP-16, and has been shown to overexpress MRP by 10 fold.

In our study, MCF7-VP cells in liquid culture were exposed to media alone, Doxorubicin (DOX) (3uM), Probenecid (0.1mM) or a combination of DOX (3uM) and Probenecid (0.1mM, 0.01mM and 1uM). Cells were incubated for 24 hours after which an MTT cell viability assay was used. The following trends were found; DOX alone reduced mean cell viability by 15.6%, Probenecid resulted in a 5.3% loss in mean viable cells, while a 32.9% drop in mean cell viability was achieved when the 2 drugs were given in combination.

In contrast, control experiments using the parental MCF7-WT and the Pgp-overexpressing MCF7-ADR cell lines showed in both cases that the addition of Probenecid had no effect on DOX drug sensitivity. Our results suggest the role of Probenecid as a potential **modulator** of drug resistance in breast cancer cells overexpressing MRP. These results are similar to those found in other, non-breast cancer MRP overexpressing

cell lines and prompt further investigation. Additional experiments using a clonogenic assay are in progress. In conclusion, this work is the first

to show that Probenecid, at clinically achievable and non-toxic concentrations, produces a **reversing** trend in the DOX resistance of the breast cancer cell line MCF7-VP. (C) American Society of Clinical Oncology 1998.

L4 ANSWER 3 OF 4

MEDLINE

DUPLICATE 1

ACCESSION NUMBER:

87033956 MEDLINE

DOCUMENT NUMBER:

87033956 PubMed ID: 3095338

TITLE:

Relation between the regulation of DNA synthesis and the production of two secreted glycoproteins by 12-O-tetradecanoylphorbol-13-acetate in 3T3 cells and in phorbol ester nonresponsive 3T3 variants.

AUTHOR:

Fienup V K; Jeng M H; Hamilton R T; Nilsen-Hamilton M

CONTRACT NUMBER:

CA39256 (NCI)

SOURCE:

JOURNAL OF CELLULAR PHYSIOLOGY, (1986 Nov) 129 (2) 151-8.

Journal code: 0050222. ISSN: 0021-9541.

PUB. COUNTRY:

United States

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

198612

ENTRY DATE:

Entered STN: 19900302

Last Updated on STN: 20020420

Entered Medline: 19861215

AB 12-O-tetradecanoylphorbol-13-acetate (TPA), a potent tumor promoter, acts similarly to growth factors by selectively increasing the rate of production of the secreted proteins, mitogen regulated protein (MRP) and major excreted protein (MEP) by murine 3T3 cells. MRP, a 34 kilodalton (kDa) glycoprotein, is a member of the prolactin-growth hormone family of proteins. MEP, a 39 kDa glycoprotein, is a lysosomal thiol protease that is also secreted. The aim of our investigation was to determine the relation between increases in MRP and MEP production and the initiation of DNA synthesis in response to mitogens. The TNR-9 cell line is a variant of 3T3 cells in which growth factors, but not TPA and teleocidin, stimulate DNA synthesis and cell division. Using [35S]methionine to metabolically label proteins and SDS polyacrylamide gel electrophoresis to resolve the proteins, we found that growing cultures of 3T3 and TNR-9 cells responded equally well to TPA and teleocidin with increased rates of production of MRP and MEP. By contrast, the responses of quiescent TNR-9 cells to these tumor promoters in the increased production of MRP and MEP was greatly diminished compared with quiescent 3T3 cells. The changes in production of MRP in response to tumor promoters in quiescent and growing cells paralleled similar changes in the level of MRP mRNA. In summary, the ability to TPA and teleocidin to increase the rate of production of MRP and MEP correlated with the ability of these tumor promoters to stimulate DNA synthesis in quiescent 3T3 and TNR-9 cells. Evidently the biochemical condition that distinguishes TNR-9 from 3T3 cells and that limits the ability of tumor promoters to stimulate the production of MEP and MRP, and perhaps also DNA synthesis in TNR-9 cells occurs only when the cells are quiescent.

L17 ANSWER 13 OF 15

MEDLINE

DUPLICATE 7

ACCESSION NUMBER: 92251199 MEDLINE  
DOCUMENT NUMBER: 92251199 PubMed ID: 1374453  
TITLE: Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro.  
AUTHOR: Sarma V; Wolf F W; Marks R M; Shows T B; Dixit V M  
CORPORATE SOURCE: Department of Pathology, University of Michigan Medical School, Ann Arbor 48109.  
CONTRACT NUMBER: HL45351 (NHLBI)  
SOURCE: JOURNAL OF IMMUNOLOGY, (1992 May 15) 148 (10) 3302-12.  
JOURNAL code: IFB; 2985117R. ISSN: 0022-1767.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
OTHER SOURCE: GENBANK-M92357  
ENTRY MONTH: 199206  
ENTRY DATE: Entered STN: 19920619  
Last Updated on STN: 19960129  
Entered Medline: 19920609

AB TNF is a proinflammatory cytokine that has pleiotropic effects on cells and tissues, mediated in large part by alterations in target tissue gene expression. We have used the technique of differential hybridization to identify several primary response genes induced by TNF in human umbilical vein endothelial (HUVE) cells, a cell type that is profoundly activated by cytokine treatment. One of these cDNA, designated **B94**, detects a rapidly and transiently induced 4-kb transcript in TNF-treated HUVE cells, and this transcript is superinduced in the concomitant presence of cycloheximide. Other proinflammatory stimuli including IL-1 beta and LPS are also able to induce **B94** mRNA expression. Nuclear run-on experiments demonstrate that TNF induction of **B94** transcript occurs primarily at the level of transcriptional activation. Further, **B94** is shown to be a single copy gene that is evolutionarily conserved. The gene is localized to the q32 region of chromosome 14, a region that is often rearranged in lymphoid neoplasms. **B94** transcript expression is also found to be regulated during mouse development and in an in vitro model of endothelial capillary tube formation. Developmental regulation occurs most prominently in mouse embryonic liver and kidney, and a second smaller form of **B94** transcript is detected in the placenta and testes. **B94** and other TNF-responsive transcripts are also induced during capillary tube formation suggesting overlap between genes induced by TNF and those induced during angiogenesis. Sequence analysis of the **B94** cDNA reveals an open reading frame encoding a 73-kDa polypeptide that has no homology to any known protein. Polyclonal antisera directed against the carboxyl-terminal portion of the **B94** protein immunoprecipitates a protein of the predicted molecular mass both from COS cells transfected with a **B94** expression vector and from TNF-treated HUVE cells.

L17 ANSWER 8 OF 15

MEDLINE

DUPLICATE 4

ACCESSION NUMBER: 94148868 MEDLINE  
DOCUMENT NUMBER: 94148868 PubMed ID: 8106408  
TITLE: **B94**, a primary response gene inducible by tumor necrosis factor-alpha, is expressed in developing hematopoietic tissues and the sperm acrosome.  
AUTHOR: Wolf F W; Sarma V; Seldin M; Drake S; Suchard S J; Shao H; O'Shea K S; Dixit V M  
CORPORATE SOURCE: Department of Pathology, University of Michigan Medical School, Ann Arbor 48109.  
CONTRACT NUMBER: HL45351 (NHLBI)  
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (1994 Feb 4) 269 (5) 3633-40.  
Journal code: HIV; 2985121R. ISSN: 0021-9258.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
OTHER SOURCE: GENBANK-L24118  
ENTRY MONTH: 199403  
ENTRY DATE: Entered STN: 19940330  
Last Updated on STN: 19940330  
Entered Medline: 19940318

AB **B94** was originally described as a novel tumor necrosis factor-alpha-inducible primary response gene in endothelial cells which was also induced in an in vitro model of angiogenesis. To further characterize its expression, we cloned the mouse homologue and mapped its developmental and tissue specific expression. The predicted amino acid sequence of mouse **B94** was found to be 83% similar to its human homologue. The gene was localized to mouse chromosome 12 just centromeric to the immunoglobulin heavy chain locus, in a region that is often rearranged in T-cell neoplasms. To explore the possibility that **B94** is expressed during vasculogenesis and other developmental processes, the expression of its transcript was determined during mouse development by in situ hybridization. In 10-day embryos **B94** was expressed prominently in the myocardium and in the aortic arch. By the 15th day of gestation, expression was restricted largely to the liver,

the

bone forming regions of the jaw, the aortic endothelium, and the nasopharynx: a pattern that was maintained until just prior to birth. Postnatally, expression shifted to the red pulp of the spleen and the thymic medulla. **B94** expression was extinguished in most adult tissues but was detectable in lymphopoietic tissues including the spleen, tonsil, and lymphatic aggregates in the gut. Consistent with this was the finding that mononuclear progenitor cells in bone marrow and mature peripheral blood monocytes expressed **B94**. A truncated testis-specific transcript previously identified by Northern blot

analysis

was determined to result from the use of an alternate polyadenylation signal which was surprisingly located within the open reading frame. This shorter transcript was expressed at high levels exclusively in late stage spermatids. Immunostaining with an affinity-purified polyclonal antiserum revealed **B94** to be localized to the acrosomal compartment of mature sperm. These studies demonstrate that **B94** expression is tightly regulated during development and suggests distinct roles for **B94** in myelopoiesis and spermatogenesis.

L24 ANSWER 17 OF 18 MEDLINE DUPLICATE 11  
ACCESSION NUMBER: 92028985 MEDLINE  
DOCUMENT NUMBER: 92028985 PubMed ID: 1834059  
TITLE: Mouse oncogene protein **24p3** is a member of the  
lipocalin protein family.  
AUTHOR: Flower D R; North A C; Attwood T K  
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology,  
University of Leeds, UK.  
SOURCE: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1991  
Oct 15) 180 (1) 69-74.  
Journal code: 9Y8; 0372516. ISSN: 0006-291X.  
PUB. COUNTRY: United States  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199111  
ENTRY DATE: Entered STN: 19920124  
Last Updated on STN: 19920124  
Entered Medline: 19911121

AB Rigorous new methods of protein sequence analysis have been applied to  
the  
lipocalins, a diverse family of ligand binding proteins. Using three  
conserved sequence motifs to search for similar patterns in a large  
sequence database, the size and composition of this protein family have  
been defined in an automatic and objective way. It has allowed the  
identification of an existing sequence, mouse 24p3 protein, as a  
lipocalin  
and the possible rejection of other putative members from this protein  
family. On the basis of this newly discovered homology, a possible  
function for mouse 24p3 protein is proposed.

L24 ANSWER 10 OF 18 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
ACCESSION NUMBER: 1997:232177 BIOSIS  
DOCUMENT NUMBER: PREV199799531380  
TITLE: High expression of the lipocalin **24p3** correlates  
with negative ER and PgR levels in breast cancer cells in  
vivo and in vitro.  
AUTHOR(S): Chen, K.-S. (1); Stoesz, S. P.; Lindstrom, M. J.; Clark,  
G.  
M.; Gould, M. N.  
CORPORATE SOURCE: (1) Dep. Human Oncol., Madison, WI 53792 USA  
SOURCE: Proceedings of the American Association for Cancer  
Research  
Annual Meeting, (1997) Vol. 38, No. 0, pp. 294.  
Meeting Info.: Eighty-eighth Annual Meeting of the  
American Association for Cancer Research San Diego, California, USA  
April 12-16, 1997  
ISSN: 0197-016X.  
DOCUMENT TYPE: Conference; Abstract  
LANGUAGE: English



L24 ANSWER 8 OF 18 CANCERLIT

ACCESSION NUMBER: 1998638976 CANCERLIT

DOCUMENT NUMBER: 98638976

TITLE: High expression of the lipocalin 24p3 correlates with negative ER and PgR levels in breast cancer cells in vivo and in vitro (Meeting abstract).

AUTHOR: Chen K-S; Stoesz S P; Lindstrom M J; Clark G M; Gould M N

CORPORATE SOURCE: Univ. Winsconsin-Madison, Depts. of Human Oncology and Biostatistics, Madison, WI 53792.

SOURCE: Proc Annu Meet Am Assoc Cancer Res, (1997). Vol. 38, pp. A1976.

ISSN: 0197-016X.

DOCUMENT TYPE: (MEETING ABSTRACTS)

FILE SEGMENT: ICDB

LANGUAGE: English

ENTRY MONTH: 199803

AB The lipocalin 24p3 has been previously reported to be associated with highly aggressive neu-induced rat mammary carcinomas. In order to extend this investigation to human breast cancer, we characterized 120 human breast carcinomas for HER2/neu amplification and 24p3 expression. Surprisingly, we found no correlation ( $p=0.5624$ ). However, we did find a strong association between high 24p3 levels and ER- ( $p=0.0001$ ) and PgR-negative status ( $p=0.0004$ ) and high S-phase fraction ( $p=0.0011$ ) in

250

breast cancer patients. These observations were extended to several breast

cancer cell lines. Cell lines negative for ER and PgR, MDA:MB-231 and T47D:C4:2W, had high levels of 24p3, while cell lines positive for both steroid receptors, T47D:A18 and MCF-7:WS8, expressed little or no 24p3.

We

are currently characterizing the human and rat 5' region of the 24p3 gene to delineate mechanisms underlying these observations. Both 5' regions have been cloned and sequenced, and found to contain several consensus binding sequences for transcriptional factors, including TATA-like box, NF-1 and NF-kB binding sites, and two negative GRE/PRE elements. These results suggest that 24p3 has the potential to serve as a downstream marker of ER/PgR-negative status in breast cancer.

L24 ANSWER 9 OF 18

MEDLINE

DUPLICATE 6

L10 ANSWER 60 OF 60 MEDLINE on STN DUPLICATE 34

ACCESSION NUMBER: 90321782 MEDLINE  
DOCUMENT NUMBER: 90321782 PubMed ID: 2640156  
TITLE: Correlation of inhibition of adhesion of large cell lymphoma and hepatic sinusoidal **endothelial** cells by RGD-containing **peptide** polymers with **metastatic** potential: role of integrin-dependent and -independent adhesion mechanisms.  
AUTHOR: Tressler R J; Belloni P N; Nicolson G L  
CORPORATE SOURCE: Department of Tumor Biology, University of Texas MD Anderson Cancer Center, Houston 77030.  
CONTRACT NUMBER: P30-CA16672 (NCI)  
R35-CA44352 (NCI)  
SOURCE: CANCER COMMUNICATIONS, (1989) 1 (1) 55-63.  
Journal code: 8916730. ISSN: 0955-3541.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199008  
ENTRY DATE: Entered STN: 19901012  
Last Updated on STN: 19970203  
Entered Medline: 19900827

AB Murine RAW117 large-cell lymphoma cells that show organ preferences of **metastatic** colonization were selected. We examined the role of adhesive systems in determining the organ preference of **metastasis** using cell lines of low (RAW117-P) and high (RAW117-H10) liver-**metastatic** potential. Highly **metastatic** H10 cells adhered at higher rates than low **metastatic** P cells to target organ microvessel **endothelial** cells, and these interactions were partially inhibited by RGD-containing polymers but not by small peptides such as GRGDS or GRGES. The most effective polymers, such as (GRGDS)4 and GRGDS(GRGES)2GRGDS, significantly inhibited H10 cell adhesion but had less effect on P cell adhesion to target liver sinusoidal **endothelial** cell monolayers or on P cell or H10 cell adhesion to bovine aortic **endothelial** cell monolayers. The (GRGDS)4 polymer reduced the rate of H10 liver sinusoidal **endothelial** cell adhesion to that of P cells in the absence of inhibitors, suggesting that the quantitative difference in adhesion of H10 cells versus P cells to liver sinusoidal **endothelial** cells may have been due to integrin-like molecules. Other RGD-containing polymers, such as (GRGES)2(GRGDS)2, GRGES(GRGDS)2GRGES, or (GRGES)4, were less effective, suggesting that the secondary structure of the polymers may be an important consideration. A peptide from the B1 chain of laminin (YIGSR) or its homopolymer, (YIGSR)4, had no effect on **endothelial** cell adhesion, consistent with the lack of differential laminin adhesion seen with various RAW117 cell lines. The results suggest that integrin-related molecules may play a role in the organ specificity of **endothelial** cell adhesion seen with RAW117 tumor cells.

L10 ANSWER 59 OF 60

MEDLINE on STN

DUPLICATE 33

ACCESSION NUMBER: 89234196 MEDLINE

DOCUMENT NUMBER: 89234196 PubMed ID: 2469686

TITLE: Human microvascular **endothelial** cells express integrin-related complexes that mediate adhesion to the extracellular matrix.

AUTHOR: Cheng Y F; Kramer R H

CORPORATE SOURCE: Department of Anatomy, School of Medicine, University of California, San Francisco 94143.

CONTRACT NUMBER: CA33834 (NCI)

SOURCE: JOURNAL OF CELLULAR PHYSIOLOGY, (1989 May) 139 (2) 275-86.

Journal code: 0050222. ISSN: 0021-9541.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198906

ENTRY DATE: Entered STN: 19900306

Last Updated on STN: 19970203

Entered Medline: 19890609

AB Microvascular **endothelial** cells (MEC) must use a set of surface receptors to adhere not only to the **vascular** basement membrane but, during **angiogenic** stimulation, to the interstitium. We examined how cultured MEC isolated from human foreskin interact with their subendothelial matrix. MEC were able to attach to diverse extracellular matrix proteins, including fibronectin (Fn), vitronectin (Vn), laminin (Ln), type I and IV collagen, as well as to fibrinogen and gelatin. Adhesion to Fn, but not to laminin or collagens, was specifically blocked in the presence of Arg-Gly-Asp (RGD)-containing **peptides**. When surface radioiodinated MEC were solubilized and subjected to affinity chromatography on Fn-Sepharose columns, two polypeptides of 150 and 125 kD, corresponding to the integrin heterodimer alpha 5 beta 1, were identified. MEC also express a complex of 150 (alpha) and 95 kD (beta 3) that is related to the Vn receptor. Immunofluorescent staining of MEC cultures with antibodies to the integrin beta 1 subunit demonstrated receptors on the basolateral surface at focal adhesion plaques that co-localized with vinculin and with Fn-positive matrix fibers. Occasionally, antibodies to the Vn receptor stained the vinculin-positive focal adhesion plaques that frequently co-localized with the beta 1 complex. However, in cultures of MEC that were attached to substrates coated with alternating strips of Fn and Vn, the beta 1 complex was preferentially localized to the Fn substrate, while the Vn receptor was concentrated on the Vn substrate. The results indicate that MEC express at least two different heterodimer adhesion receptors that belong to the integrin super-family and appear to have distinct ligand specificities: the Fn receptor and the Vn receptor. These receptors mediate cell adhesion to the extracellular matrix and presumably have an important role in hemostasis and neovascularization.

L10 ANSWER 56 OF 60

MEDLINE on STN

DUPLICATE 32

ACCESSION NUMBER: 91339170 MEDLINE

DOCUMENT NUMBER: 91339170 PubMed ID: 1908352

TITLE: Effect of inflammatory cytokines on the adherence of **tumor** cells to **endothelium** in a murine model.

AUTHOR: Bereta M; Bereta J; Cohen S; Zaifert K; Cohen M C

CORPORATE SOURCE: Department of Pathology and Laboratory Medicine, Hahnemann University, Philadelphia, Pennsylvania 19102.

CONTRACT NUMBER: CA-32319 (NCI)

CA-39723 (NCI)

SOURCE: CELLULAR IMMUNOLOGY, (1991 Sep) 136 (2) 263-77.

Journal code: 1246405. ISSN: 0008-8749.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199109

ENTRY DATE: Entered STN: 19911013

Last Updated on STN: 19970203

Entered Medline: 19910920

AB We have demonstrated that pretreatment of mouse brain microvascular **endothelial** cells (MBE) with **tumor** necrosis factor-alpha (TNF), IL-1, or LPS augmented the binding of P815 mastocytoma cells in vitro. The effect of these agents was dose and time dependent. PMA was able to mimic the influence of these factors to a limited degree. The effect of TNF on **endothelium** was accompanied by the appearance of changes in the expression of proteins isolated from **endothelial** cell membranes. The adherence of **tumor** cells to **endothelium** was not inhibited by RGD-containing **peptides** but could be decreased by preincubation of **endothelium** with high concentrations of FCS. Our data suggest that cytokines regulate the synthesis of **endothelial** adhesion proteins which may be involved in **tumor** cell adherence leading to **metastasis**. These results raise the possibility that cytokines may exert paradoxical effects in vivo, i.e., a cytotoxic effect that reduces **tumor** mass accompanied by a **metastasis** -enhancing effect that actually promotes dissemination of the remaining **tumor** cells. Definition of the molecular events involved in **tumor** cell-**endothelial** cell interactions may lead to strategies for minimizing the latter effect in therapeutic settings.